id	sid	tid	token	lemma	pos
easat-8653	1	1	edelweiss	edelweiss	PROPN
easat-8653	1	2	applied	apply	VERB
easat-8653	1	3	science	science	NOUN
easat-8653	1	4	and	and	CCONJ
easat-8653	1	5	technology	technology	NOUN
easat-8653	1	6	issn	issn	PROPN
easat-8653	1	7	:	:	PUNCT
easat-8653	1	8	2576	2576	NUM
easat-8653	1	9	-	-	SYM
easat-8653	1	10	8484	8484	NUM
easat-8653	1	11	vol	vol	NOUN
easat-8653	1	12	.	.	PROPN
easat-8653	2	1	9	9	NUM
easat-8653	2	2	,	,	PUNCT
easat-8653	2	3	no	no	INTJ
easat-8653	2	4	.	.	NOUN
easat-8653	2	5	7	7	NUM
easat-8653	2	6	,	,	PUNCT
easat-8653	2	7	529	529	NUM
easat-8653	2	8	-	-	SYM
easat-8653	2	9	535	535	NUM
easat-8653	2	10	2025	2025	NUM
easat-8653	2	11	publisher	publisher	NOUN
easat-8653	2	12	:	:	PUNCT
easat-8653	2	13	learning	learn	VERB
easat-8653	2	14	gate	gate	NOUN
easat-8653	2	15	doi	doi	PROPN
easat-8653	2	16	:	:	PUNCT
easat-8653	2	17	10.55214/25768484.v9i7.8653	10.55214/25768484.v9i7.8653	PROPN
easat-8653	2	18	©	©	PROPN
easat-8653	2	19	2025	2025	NUM
easat-8653	2	20	by	by	ADP
easat-8653	2	21	the	the	DET
easat-8653	2	22	authors	author	NOUN
easat-8653	2	23	;	;	PUNCT
easat-8653	2	24	licensee	licensee	PROPN
easat-8653	2	25	learning	learning	NOUN
easat-8653	2	26	gate	gate	NOUN
easat-8653	3	1	©	©	PROPN
easat-8653	3	2	2025	2025	NUM
easat-8653	3	3	by	by	ADP
easat-8653	3	4	the	the	DET
easat-8653	3	5	authors	author	NOUN
easat-8653	3	6	;	;	PUNCT
easat-8653	3	7	licensee	licensee	PROPN
easat-8653	3	8	learning	learning	NOUN
easat-8653	3	9	gate	gate	NOUN
easat-8653	3	10	history	history	NOUN
easat-8653	3	11	:	:	PUNCT
easat-8653	3	12	received	receive	VERB
easat-8653	3	13	:	:	PUNCT
easat-8653	3	14	1	1	NUM
easat-8653	3	15	april	april	PROPN
easat-8653	3	16	2025	2025	NUM
easat-8653	3	17	;	;	PUNCT
easat-8653	3	18	revised	revise	VERB
easat-8653	3	19	:	:	PUNCT
easat-8653	3	20	6	6	NUM
easat-8653	3	21	june	june	PROPN
easat-8653	3	22	2025	2025	NUM
easat-8653	3	23	;	;	PUNCT
easat-8653	3	24	accepted	accept	VERB
easat-8653	3	25	:	:	PUNCT
easat-8653	3	26	9	9	NUM
easat-8653	3	27	june	june	PROPN
easat-8653	3	28	2025	2025	NUM
easat-8653	3	29	;	;	PUNCT
easat-8653	3	30	published	publish	VERB
easat-8653	3	31	:	:	PUNCT
easat-8653	3	32	7	7	NUM
easat-8653	3	33	july	july	PROPN
easat-8653	3	34	2025	2025	NUM
easat-8653	3	35	*	*	PUNCT
easat-8653	3	36	correspondence	correspondence	NOUN
easat-8653	3	37	:	:	PUNCT
easat-8653	4	1	muhamadhusnithamrinhamdani@gmail.com	muhamadhusnithamrinhamdani@gmail.com	X
easat-8653	4	2	comparison	comparison	NOUN
easat-8653	4	3	of	of	ADP
easat-8653	4	4	mortality	mortality	NOUN
easat-8653	4	5	rates	rate	NOUN
easat-8653	4	6	in	in	ADP
easat-8653	4	7	solid	solid	ADJ
easat-8653	4	8	vs	vs	ADP
easat-8653	4	9	hematological	hematological	ADJ
easat-8653	4	10	cancer	cancer	NOUN
easat-8653	4	11	patients	patient	NOUN
easat-8653	4	12	post	post	VERB
easat-8653	4	13	covid-19	covid-19	PROPN
easat-8653	4	14	treatment	treatment	NOUN
easat-8653	4	15	at	at	ADP
easat-8653	4	16	dr	dr	PROPN
easat-8653	4	17	.	.	PROPN
easat-8653	4	18	soetomo	soetomo	PROPN
easat-8653	4	19	general	general	PROPN
easat-8653	4	20	hospital	hospital	PROPN
easat-8653	4	21	,	,	PUNCT
easat-8653	4	22	surabaya	surabaya	PROPN
easat-8653	4	23	(	(	PUNCT
easat-8653	4	24	2020–2021	2020–2021	NUM
easat-8653	4	25	)	)	PUNCT
easat-8653	4	26	muhamad	muhamad	PROPN
easat-8653	4	27	husni	husni	PROPN
easat-8653	4	28	thamrin	thamrin	NOUN
easat-8653	4	29	hamdani1	hamdani1	NOUN
easat-8653	4	30	*	*	NOUN
easat-8653	4	31	,	,	PUNCT
easat-8653	4	32	wahyuhadi	wahyuhadi	NOUN
easat-8653	4	33	,	,	PUNCT
easat-8653	4	34	joni1	joni1	PROPN
easat-8653	4	35	,	,	PUNCT
easat-8653	4	36	susilo	susilo	ADJ
easat-8653	4	37	,	,	PUNCT
easat-8653	4	38	rahadian	rahadian	ADJ
easat-8653	4	39	indarto1	indarto1	PROPN
easat-8653	4	40	,	,	PUNCT
easat-8653	4	41	utomo	utomo	ADJ
easat-8653	4	42	,	,	PUNCT
easat-8653	4	43	budi1	budi1	NOUN
easat-8653	5	1	1department	1department	NUM
easat-8653	5	2	of	of	ADP
easat-8653	5	3	neurosurgery	neurosurgery	NOUN
easat-8653	5	4	,	,	PUNCT
easat-8653	5	5	faculty	faculty	NOUN
easat-8653	5	6	of	of	ADP
easat-8653	5	7	medicine	medicine	NOUN
easat-8653	5	8	,	,	PUNCT
easat-8653	5	9	universitas	universita	NOUN
easat-8653	5	10	airlangga	airlangga	NOUN
easat-8653	5	11	,	,	PUNCT
easat-8653	5	12	surabaya	surabaya	PROPN
easat-8653	5	13	,	,	PUNCT
easat-8653	5	14	indonesia	indonesia	PROPN
easat-8653	5	15	;	;	PUNCT
easat-8653	6	1	muhamadhusnithamrinhamdani@gmail.com	muhamadhusnithamrinhamdani@gmail.com	PROPN
easat-8653	6	2	(	(	PUNCT
easat-8653	6	3	m.h.t.h	m.h.t.h	PROPN
easat-8653	6	4	.	.	PUNCT
easat-8653	6	5	)	)	PUNCT
easat-8653	7	1	dr_rahadian_ns@yahoo.co.id	dr_rahadian_ns@yahoo.co.id	NOUN
easat-8653	7	2	(	(	PUNCT
easat-8653	7	3	w.j	w.j	PROPN
easat-8653	7	4	.	.	PUNCT
easat-8653	7	5	)	)	PUNCT
easat-8653	8	1	joniwahyuhadi@yahoo.com	joniwahyuhadi@yahoo.com	X
easat-8653	8	2	(	(	PUNCT
easat-8653	8	3	s.r.i	s.r.i	NOUN
easat-8653	8	4	.	.	PUNCT
easat-8653	8	5	)	)	PUNCT
easat-8653	9	1	budiutomo@fk.unair.ac.id	budiutomo@fk.unair.ac.id	NOUN
easat-8653	9	2	(	(	PUNCT
easat-8653	9	3	u.b	u.b	PROPN
easat-8653	9	4	.	.	PUNCT
easat-8653	9	5	)	)	PUNCT
easat-8653	10	1	abstract	abstract	NOUN
easat-8653	10	2	:	:	PUNCT
easat-8653	10	3	the	the	DET
easat-8653	10	4	covid-19	covid-19	PROPN
easat-8653	10	5	pandemic	pandemic	NOUN
easat-8653	10	6	significantly	significantly	ADV
easat-8653	10	7	impacted	impact	VERB
easat-8653	10	8	cancer	cancer	NOUN
easat-8653	10	9	patients	patient	NOUN
easat-8653	10	10	due	due	ADP
easat-8653	10	11	to	to	ADP
easat-8653	10	12	their	their	PRON
easat-8653	10	13	immunocompromised	immunocompromise	VERB
easat-8653	10	14	status	status	NOUN
easat-8653	10	15	and	and	CCONJ
easat-8653	10	16	comorbid	comorbid	NOUN
easat-8653	10	17	conditions	condition	NOUN
easat-8653	10	18	.	.	PUNCT
easat-8653	11	1	however	however	ADV
easat-8653	11	2	,	,	PUNCT
easat-8653	11	3	comparative	comparative	ADJ
easat-8653	11	4	data	datum	NOUN
easat-8653	11	5	on	on	ADP
easat-8653	11	6	mortality	mortality	NOUN
easat-8653	11	7	outcomes	outcome	NOUN
easat-8653	11	8	between	between	ADP
easat-8653	11	9	solid	solid	ADJ
easat-8653	11	10	and	and	CCONJ
easat-8653	11	11	hematological	hematological	ADJ
easat-8653	11	12	cancer	cancer	NOUN
easat-8653	11	13	patients	patient	NOUN
easat-8653	11	14	post	post	ADJ
easat-8653	11	15	-	-	ADJ
easat-8653	11	16	covid-19	covid-19	ADJ
easat-8653	11	17	treatment	treatment	NOUN
easat-8653	11	18	remains	remain	VERB
easat-8653	11	19	limited	limited	ADJ
easat-8653	11	20	.	.	PUNCT
easat-8653	12	1	this	this	DET
easat-8653	12	2	study	study	NOUN
easat-8653	12	3	aimed	aim	VERB
easat-8653	12	4	to	to	PART
easat-8653	12	5	analyze	analyze	VERB
easat-8653	12	6	the	the	DET
easat-8653	12	7	mortality	mortality	NOUN
easat-8653	12	8	differences	difference	NOUN
easat-8653	12	9	in	in	ADP
easat-8653	12	10	these	these	DET
easat-8653	12	11	groups	group	NOUN
easat-8653	12	12	at	at	ADP
easat-8653	12	13	dr	dr	PROPN
easat-8653	12	14	.	.	PROPN
easat-8653	12	15	soetomo	soetomo	PROPN
easat-8653	12	16	general	general	PROPN
easat-8653	12	17	hospital	hospital	PROPN
easat-8653	12	18	,	,	PUNCT
easat-8653	12	19	surabaya	surabaya	PROPN
easat-8653	12	20	,	,	PUNCT
easat-8653	12	21	between	between	ADP
easat-8653	12	22	2020	2020	NUM
easat-8653	12	23	and	and	CCONJ
easat-8653	12	24	2021	2021	NUM
easat-8653	12	25	.	.	PUNCT
easat-8653	13	1	a	a	DET
easat-8653	13	2	retrospective	retrospective	ADJ
easat-8653	13	3	cohort	cohort	NOUN
easat-8653	13	4	analysis	analysis	NOUN
easat-8653	13	5	was	be	AUX
easat-8653	13	6	conducted	conduct	VERB
easat-8653	13	7	using	use	VERB
easat-8653	13	8	patient	patient	ADJ
easat-8653	13	9	medical	medical	ADJ
easat-8653	13	10	records	record	NOUN
easat-8653	13	11	.	.	PUNCT
easat-8653	14	1	inclusion	inclusion	NOUN
easat-8653	14	2	criteria	criterion	NOUN
easat-8653	14	3	covered	cover	VERB
easat-8653	14	4	cancer	cancer	NOUN
easat-8653	14	5	patients	patient	NOUN
easat-8653	14	6	confirmed	confirm	VERB
easat-8653	14	7	with	with	ADP
easat-8653	14	8	covid-19	covid-19	PROPN
easat-8653	14	9	who	who	PRON
easat-8653	14	10	underwent	undergo	VERB
easat-8653	14	11	treatment	treatment	NOUN
easat-8653	14	12	and	and	CCONJ
easat-8653	14	13	had	have	VERB
easat-8653	14	14	complete	complete	ADJ
easat-8653	14	15	mortality	mortality	NOUN
easat-8653	14	16	outcome	outcome	NOUN
easat-8653	14	17	data	datum	NOUN
easat-8653	14	18	.	.	PUNCT
easat-8653	15	1	variables	variable	NOUN
easat-8653	15	2	included	include	VERB
easat-8653	15	3	cancer	cancer	NOUN
easat-8653	15	4	type	type	NOUN
easat-8653	15	5	,	,	PUNCT
easat-8653	15	6	comorbidities	comorbiditie	NOUN
easat-8653	15	7	,	,	PUNCT
easat-8653	15	8	gender	gender	NOUN
easat-8653	15	9	,	,	PUNCT
easat-8653	15	10	and	and	CCONJ
easat-8653	15	11	mortality	mortality	NOUN
easat-8653	15	12	.	.	PUNCT
easat-8653	16	1	statistical	statistical	ADJ
easat-8653	16	2	analysis	analysis	NOUN
easat-8653	16	3	involved	involve	VERB
easat-8653	16	4	chi	chi	ADJ
easat-8653	16	5	-	-	PUNCT
easat-8653	16	6	square	square	ADJ
easat-8653	16	7	tests	test	NOUN
easat-8653	16	8	and	and	CCONJ
easat-8653	16	9	multivariate	multivariate	VERB
easat-8653	16	10	logistic	logistic	ADJ
easat-8653	16	11	regression	regression	NOUN
easat-8653	16	12	.	.	PUNCT
easat-8653	17	1	among	among	ADP
easat-8653	17	2	237	237	NUM
easat-8653	17	3	patients	patient	NOUN
easat-8653	17	4	,	,	PUNCT
easat-8653	17	5	78	78	NUM
easat-8653	17	6	%	%	NOUN
easat-8653	17	7	had	have	VERB
easat-8653	17	8	solid	solid	ADJ
easat-8653	17	9	tumors	tumor	NOUN
easat-8653	17	10	,	,	PUNCT
easat-8653	17	11	and	and	CCONJ
easat-8653	17	12	74.7	74.7	NUM
easat-8653	17	13	%	%	NOUN
easat-8653	17	14	had	have	VERB
easat-8653	17	15	comorbidities	comorbiditie	NOUN
easat-8653	17	16	.	.	PUNCT
easat-8653	18	1	no	no	DET
easat-8653	18	2	statistically	statistically	ADV
easat-8653	18	3	significant	significant	ADJ
easat-8653	18	4	difference	difference	NOUN
easat-8653	18	5	in	in	ADP
easat-8653	18	6	mortality	mortality	NOUN
easat-8653	18	7	was	be	AUX
easat-8653	18	8	observed	observe	VERB
easat-8653	18	9	between	between	ADP
easat-8653	18	10	cancer	cancer	NOUN
easat-8653	18	11	types	type	NOUN
easat-8653	18	12	(	(	PUNCT
easat-8653	18	13	p	p	X
easat-8653	18	14	>	>	X
easat-8653	18	15	0.05	0.05	NUM
easat-8653	18	16	)	)	PUNCT
easat-8653	18	17	.	.	PUNCT
easat-8653	19	1	however	however	ADV
easat-8653	19	2	,	,	PUNCT
easat-8653	19	3	comorbidities	comorbiditie	NOUN
easat-8653	19	4	significantly	significantly	ADV
easat-8653	19	5	influenced	influence	VERB
easat-8653	19	6	mortality	mortality	NOUN
easat-8653	19	7	risk	risk	NOUN
easat-8653	19	8	(	(	PUNCT
easat-8653	19	9	p	p	X
easat-8653	19	10	<	<	X
easat-8653	19	11	0.001	0.001	NUM
easat-8653	19	12	;	;	PUNCT
easat-8653	19	13	rr	rr	NOUN
easat-8653	19	14	=	=	PROPN
easat-8653	19	15	25.08	25.08	NUM
easat-8653	19	16	;	;	PUNCT
easat-8653	19	17	95	95	NUM
easat-8653	19	18	%	%	NOUN
easat-8653	19	19	ci	ci	NOUN
easat-8653	19	20	:	:	PUNCT
easat-8653	19	21	3.56–176.55	3.56–176.55	NUM
easat-8653	19	22	)	)	PUNCT
easat-8653	19	23	.	.	PUNCT
easat-8653	20	1	comorbidities	comorbiditie	NOUN
easat-8653	20	2	are	be	AUX
easat-8653	20	3	a	a	DET
easat-8653	20	4	major	major	ADJ
easat-8653	20	5	determinant	determinant	NOUN
easat-8653	20	6	of	of	ADP
easat-8653	20	7	mortality	mortality	NOUN
easat-8653	20	8	among	among	ADP
easat-8653	20	9	cancer	cancer	NOUN
easat-8653	20	10	patients	patient	NOUN
easat-8653	20	11	recovering	recover	VERB
easat-8653	20	12	from	from	ADP
easat-8653	20	13	covid-19	covid-19	PROPN
easat-8653	20	14	,	,	PUNCT
easat-8653	20	15	regardless	regardless	ADV
easat-8653	20	16	of	of	ADP
easat-8653	20	17	cancer	cancer	NOUN
easat-8653	20	18	type	type	NOUN
easat-8653	20	19	.	.	PUNCT
easat-8653	21	1	addressing	address	VERB
easat-8653	21	2	comorbid	comorbid	NOUN
easat-8653	21	3	conditions	condition	NOUN
easat-8653	21	4	aggressively	aggressively	ADV
easat-8653	21	5	may	may	AUX
easat-8653	21	6	reduce	reduce	VERB
easat-8653	21	7	fatal	fatal	ADJ
easat-8653	21	8	outcomes	outcome	NOUN
easat-8653	21	9	in	in	ADP
easat-8653	21	10	this	this	DET
easat-8653	21	11	vulnerable	vulnerable	ADJ
easat-8653	21	12	population	population	NOUN
easat-8653	21	13	.	.	PUNCT
easat-8653	22	1	keywords	keyword	NOUN
easat-8653	22	2	:	:	PUNCT
easat-8653	22	3	comorbidity	comorbidity	NOUN
easat-8653	22	4	,	,	PUNCT
easat-8653	22	5	covid-19	covid-19	PROPN
easat-8653	22	6	,	,	PUNCT
easat-8653	22	7	hematological	hematological	ADJ
easat-8653	22	8	cancer	cancer	NOUN
easat-8653	22	9	,	,	PUNCT
easat-8653	22	10	mortality	mortality	NOUN
easat-8653	22	11	,	,	PUNCT
easat-8653	22	12	solid	solid	ADJ
easat-8653	22	13	cancer	cancer	NOUN
easat-8653	22	14	.	.	PUNCT
easat-8653	23	1	1	1	X
easat-8653	23	2	.	.	X
easat-8653	23	3	introduction	introduction	NOUN
easat-8653	23	4	the	the	DET
easat-8653	23	5	coronavirus	coronavirus	NOUN
easat-8653	23	6	disease	disease	NOUN
easat-8653	23	7	2019	2019	NUM
easat-8653	23	8	(	(	PUNCT
easat-8653	23	9	covid-19	covid-19	PROPN
easat-8653	23	10	)	)	PUNCT
easat-8653	23	11	,	,	PUNCT
easat-8653	23	12	caused	cause	VERB
easat-8653	23	13	by	by	ADP
easat-8653	23	14	the	the	DET
easat-8653	23	15	sars	sar	NOUN
easat-8653	23	16	-	-	PUNCT
easat-8653	23	17	cov-2	cov-2	PART
easat-8653	23	18	virus	virus	NOUN
easat-8653	23	19	,	,	PUNCT
easat-8653	23	20	has	have	AUX
easat-8653	23	21	had	have	VERB
easat-8653	23	22	a	a	DET
easat-8653	23	23	profound	profound	ADJ
easat-8653	23	24	global	global	ADJ
easat-8653	23	25	impact	impact	NOUN
easat-8653	23	26	,	,	PUNCT
easat-8653	23	27	particularly	particularly	ADV
easat-8653	23	28	on	on	ADP
easat-8653	23	29	patients	patient	NOUN
easat-8653	23	30	with	with	ADP
easat-8653	23	31	comorbid	comorbid	NOUN
easat-8653	23	32	conditions	condition	NOUN
easat-8653	23	33	such	such	ADJ
easat-8653	23	34	as	as	ADP
easat-8653	23	35	cancer	cancer	NOUN
easat-8653	23	36	[	[	X
easat-8653	23	37	1	1	NUM
easat-8653	23	38	]	]	PUNCT
easat-8653	23	39	.	.	PUNCT
easat-8653	24	1	immunosuppression	immunosuppression	NOUN
easat-8653	24	2	and	and	CCONJ
easat-8653	24	3	systemic	systemic	ADJ
easat-8653	24	4	fragility	fragility	NOUN
easat-8653	24	5	render	render	VERB
easat-8653	24	6	cancer	cancer	NOUN
easat-8653	24	7	patients	patient	NOUN
easat-8653	24	8	more	more	ADV
easat-8653	24	9	susceptible	susceptible	ADJ
easat-8653	24	10	to	to	ADP
easat-8653	24	11	severe	severe	ADJ
easat-8653	24	12	complications	complication	NOUN
easat-8653	24	13	and	and	CCONJ
easat-8653	24	14	increased	increase	VERB
easat-8653	24	15	mortality	mortality	NOUN
easat-8653	24	16	from	from	ADP
easat-8653	24	17	covid-19	covid-19	PROPN
easat-8653	24	18	.	.	PUNCT
easat-8653	25	1	previous	previous	ADJ
easat-8653	25	2	coronaviruses	coronaviruse	NOUN
easat-8653	25	3	,	,	PUNCT
easat-8653	25	4	including	include	VERB
easat-8653	25	5	sars	sar	NOUN
easat-8653	25	6	-	-	PUNCT
easat-8653	25	7	cov	cov	PROPN
easat-8653	25	8	and	and	CCONJ
easat-8653	25	9	mers	mer	NOUN
easat-8653	25	10	-	-	PUNCT
easat-8653	25	11	cov	cov	NOUN
easat-8653	25	12	,	,	PUNCT
easat-8653	25	13	also	also	ADV
easat-8653	25	14	demonstrated	demonstrate	VERB
easat-8653	25	15	elevated	elevated	ADJ
easat-8653	25	16	morbidity	morbidity	NOUN
easat-8653	25	17	and	and	CCONJ
easat-8653	25	18	mortality	mortality	NOUN
easat-8653	25	19	in	in	ADP
easat-8653	25	20	vulnerable	vulnerable	ADJ
easat-8653	25	21	populations	population	NOUN
easat-8653	25	22	[	[	X
easat-8653	25	23	2	2	NUM
easat-8653	25	24	]	]	PUNCT
easat-8653	25	25	.	.	PUNCT
easat-8653	26	1	however	however	ADV
easat-8653	26	2	,	,	PUNCT
easat-8653	26	3	data	datum	NOUN
easat-8653	26	4	directly	directly	ADV
easat-8653	26	5	comparing	compare	VERB
easat-8653	26	6	outcomes	outcome	NOUN
easat-8653	26	7	between	between	ADP
easat-8653	26	8	solid	solid	ADJ
easat-8653	26	9	and	and	CCONJ
easat-8653	26	10	hematological	hematological	ADJ
easat-8653	26	11	cancer	cancer	NOUN
easat-8653	26	12	types	type	NOUN
easat-8653	26	13	postcovid-19	postcovid-19	PROPN
easat-8653	26	14	treatment	treatment	NOUN
easat-8653	26	15	remain	remain	VERB
easat-8653	26	16	scarce	scarce	ADJ
easat-8653	26	17	.	.	PUNCT
easat-8653	27	1	in	in	ADP
easat-8653	27	2	early	early	ADJ
easat-8653	27	3	studies	study	NOUN
easat-8653	27	4	,	,	PUNCT
easat-8653	27	5	cancer	cancer	NOUN
easat-8653	27	6	patients	patient	NOUN
easat-8653	27	7	constituted	constitute	VERB
easat-8653	27	8	approximately	approximately	ADV
easat-8653	27	9	2.1	2.1	NUM
easat-8653	27	10	%	%	NOUN
easat-8653	27	11	of	of	ADP
easat-8653	27	12	confirmed	confirm	VERB
easat-8653	27	13	covid-19	covid-19	PROPN
easat-8653	27	14	cases	case	NOUN
easat-8653	27	15	,	,	PUNCT
easat-8653	27	16	with	with	ADP
easat-8653	27	17	mortality	mortality	NOUN
easat-8653	27	18	rates	rate	NOUN
easat-8653	27	19	reaching	reach	VERB
easat-8653	27	20	21.1	21.1	NUM
easat-8653	27	21	%	%	NOUN
easat-8653	27	22	[	[	X
easat-8653	27	23	3	3	NUM
easat-8653	27	24	]	]	PUNCT
easat-8653	27	25	.	.	PUNCT
easat-8653	28	1	hematological	hematological	ADJ
easat-8653	28	2	malignancies	malignancy	NOUN
easat-8653	28	3	in	in	ADP
easat-8653	28	4	particular	particular	ADJ
easat-8653	28	5	have	have	AUX
easat-8653	28	6	been	be	AUX
easat-8653	28	7	linked	link	VERB
easat-8653	28	8	with	with	ADP
easat-8653	28	9	more	more	ADV
easat-8653	28	10	severe	severe	ADJ
easat-8653	28	11	disease	disease	NOUN
easat-8653	28	12	progression	progression	NOUN
easat-8653	28	13	and	and	CCONJ
easat-8653	28	14	immune	immune	ADJ
easat-8653	28	15	compromise	compromise	NOUN
easat-8653	28	16	.	.	PUNCT
easat-8653	29	1	nevertheless	nevertheless	ADV
easat-8653	29	2	,	,	PUNCT
easat-8653	29	3	the	the	DET
easat-8653	29	4	influence	influence	NOUN
easat-8653	29	5	of	of	ADP
easat-8653	29	6	cancer	cancer	NOUN
easat-8653	29	7	type	type	NOUN
easat-8653	29	8	—	—	PUNCT
easat-8653	29	9	solid	solid	ADJ
easat-8653	29	10	versus	versus	ADP
easat-8653	29	11	hematological	hematological	NOUN
easat-8653	29	12	—	—	PUNCT
easat-8653	29	13	on	on	ADP
easat-8653	29	14	mortality	mortality	NOUN
easat-8653	29	15	remains	remain	VERB
easat-8653	29	16	a	a	DET
easat-8653	29	17	subject	subject	NOUN
easat-8653	29	18	of	of	ADP
easat-8653	29	19	clinical	clinical	ADJ
easat-8653	29	20	inquiry	inquiry	NOUN
easat-8653	29	21	[	[	X
easat-8653	29	22	4	4	NUM
easat-8653	29	23	-	-	SYM
easat-8653	29	24	6	6	NUM
easat-8653	29	25	]	]	PUNCT
easat-8653	29	26	.	.	PUNCT
easat-8653	30	1	understanding	understanding	NOUN
easat-8653	30	2	which	which	PRON
easat-8653	30	3	factors	factor	VERB
easat-8653	30	4	most	most	ADV
easat-8653	30	5	contribute	contribute	VERB
easat-8653	30	6	to	to	ADP
easat-8653	30	7	poor	poor	ADJ
easat-8653	30	8	outcomes	outcome	NOUN
easat-8653	30	9	in	in	ADP
easat-8653	30	10	cancer	cancer	NOUN
easat-8653	30	11	patients	patient	NOUN
easat-8653	30	12	following	follow	VERB
easat-8653	30	13	covid-19	covid-19	PROPN
easat-8653	30	14	is	be	AUX
easat-8653	30	15	essential	essential	ADJ
easat-8653	30	16	for	for	ADP
easat-8653	30	17	tailoring	tailor	VERB
easat-8653	30	18	effective	effective	ADJ
easat-8653	30	19	treatment	treatment	NOUN
easat-8653	30	20	and	and	CCONJ
easat-8653	30	21	follow	follow	VERB
easat-8653	30	22	-	-	PUNCT
easat-8653	30	23	up	up	ADP
easat-8653	30	24	strategies	strategy	NOUN
easat-8653	30	25	.	.	PUNCT
easat-8653	31	1	this	this	DET
easat-8653	31	2	study	study	NOUN
easat-8653	31	3	investigates	investigate	VERB
easat-8653	31	4	mortality	mortality	NOUN
easat-8653	31	5	differences	difference	NOUN
easat-8653	31	6	between	between	ADP
easat-8653	31	7	solid	solid	ADJ
easat-8653	31	8	and	and	CCONJ
easat-8653	31	9	hematological	hematological	ADJ
easat-8653	31	10	cancer	cancer	NOUN
easat-8653	31	11	patients	patient	NOUN
easat-8653	31	12	after	after	ADP
easat-8653	31	13	covid-19	covid-19	PROPN
easat-8653	31	14	treatment	treatment	NOUN
easat-8653	31	15	at	at	ADP
easat-8653	31	16	dr	dr	PROPN
easat-8653	31	17	.	.	PROPN
easat-8653	31	18	soetomo	soetomo	PROPN
easat-8653	31	19	general	general	PROPN
easat-8653	31	20	hospital	hospital	PROPN
easat-8653	31	21	in	in	ADP
easat-8653	31	22	surabaya	surabaya	PROPN
easat-8653	31	23	during	during	ADP
easat-8653	31	24	the	the	DET
easat-8653	31	25	2020–2021	2020–2021	NUM
easat-8653	31	26	pandemic	pandemic	ADJ
easat-8653	31	27	period	period	NOUN
easat-8653	31	28	.	.	PUNCT
easat-8653	32	1	530	530	NUM
easat-8653	32	2	edelweiss	edelweiss	PROPN
easat-8653	32	3	applied	apply	VERB
easat-8653	32	4	science	science	NOUN
easat-8653	32	5	and	and	CCONJ
easat-8653	32	6	technology	technology	NOUN
easat-8653	32	7	issn	issn	PROPN
easat-8653	32	8	:	:	PUNCT
easat-8653	32	9	2576	2576	NUM
easat-8653	32	10	-	-	SYM
easat-8653	32	11	8484	8484	NUM
easat-8653	32	12	vol	vol	NOUN
easat-8653	32	13	.	.	PROPN
easat-8653	33	1	9	9	NUM
easat-8653	33	2	,	,	PUNCT
easat-8653	33	3	no	no	INTJ
easat-8653	33	4	.	.	NOUN
easat-8653	33	5	7	7	NUM
easat-8653	33	6	:	:	PUNCT
easat-8653	33	7	529	529	NUM
easat-8653	33	8	-	-	SYM
easat-8653	33	9	535	535	NUM
easat-8653	33	10	,	,	PUNCT
easat-8653	33	11	2025	2025	NUM
easat-8653	33	12	doi	doi	NOUN
easat-8653	33	13	:	:	PUNCT
easat-8653	33	14	10.55214/25768484.v9i7.8653	10.55214/25768484.v9i7.8653	PROPN
easat-8653	33	15	©	©	PROPN
easat-8653	33	16	2025	2025	NUM
easat-8653	33	17	by	by	ADP
easat-8653	33	18	the	the	DET
easat-8653	33	19	authors	author	NOUN
easat-8653	33	20	;	;	PUNCT
easat-8653	33	21	licensee	licensee	PROPN
easat-8653	33	22	learning	learning	NOUN
easat-8653	33	23	gate	gate	NOUN
easat-8653	33	24	2	2	NUM
easat-8653	33	25	.	.	PUNCT
easat-8653	33	26	methods	method	NOUN
easat-8653	33	27	this	this	DET
easat-8653	33	28	study	study	NOUN
easat-8653	33	29	employed	employ	VERB
easat-8653	33	30	a	a	DET
easat-8653	33	31	retrospective	retrospective	ADJ
easat-8653	33	32	cohort	cohort	NOUN
easat-8653	33	33	design	design	NOUN
easat-8653	33	34	conducted	conduct	VERB
easat-8653	33	35	at	at	ADP
easat-8653	33	36	dr	dr	PROPN
easat-8653	33	37	.	.	PROPN
easat-8653	33	38	soetomo	soetomo	PROPN
easat-8653	33	39	general	general	PROPN
easat-8653	33	40	hospital	hospital	PROPN
easat-8653	33	41	,	,	PUNCT
easat-8653	33	42	surabaya	surabaya	PROPN
easat-8653	33	43	,	,	PUNCT
easat-8653	33	44	indonesia	indonesia	PROPN
easat-8653	33	45	.	.	PUNCT
easat-8653	34	1	the	the	DET
easat-8653	34	2	timeframe	timeframe	NOUN
easat-8653	34	3	included	include	VERB
easat-8653	34	4	patients	patient	NOUN
easat-8653	34	5	treated	treat	VERB
easat-8653	34	6	from	from	ADP
easat-8653	34	7	march	march	PROPN
easat-8653	34	8	2020	2020	NUM
easat-8653	34	9	through	through	ADP
easat-8653	34	10	december	december	PROPN
easat-8653	34	11	2021	2021	NUM
easat-8653	34	12	.	.	PUNCT
easat-8653	35	1	the	the	DET
easat-8653	35	2	study	study	NOUN
easat-8653	35	3	population	population	NOUN
easat-8653	35	4	consisted	consist	VERB
easat-8653	35	5	of	of	ADP
easat-8653	35	6	adult	adult	NOUN
easat-8653	35	7	cancer	cancer	NOUN
easat-8653	35	8	patients	patient	NOUN
easat-8653	35	9	who	who	PRON
easat-8653	35	10	were	be	AUX
easat-8653	35	11	diagnosed	diagnose	VERB
easat-8653	35	12	with	with	ADP
easat-8653	35	13	covid-19	covid-19	PROPN
easat-8653	35	14	and	and	CCONJ
easat-8653	35	15	received	receive	VERB
easat-8653	35	16	inpatient	inpatient	NOUN
easat-8653	35	17	treatment	treatment	NOUN
easat-8653	35	18	.	.	PUNCT
easat-8653	36	1	both	both	DET
easat-8653	36	2	solid	solid	ADJ
easat-8653	36	3	and	and	CCONJ
easat-8653	36	4	hematological	hematological	ADJ
easat-8653	36	5	cancer	cancer	NOUN
easat-8653	36	6	types	type	NOUN
easat-8653	36	7	were	be	AUX
easat-8653	36	8	included	include	VERB
easat-8653	36	9	.	.	PUNCT
easat-8653	37	1	patients	patient	NOUN
easat-8653	37	2	with	with	ADP
easat-8653	37	3	incomplete	incomplete	ADJ
easat-8653	37	4	records	record	NOUN
easat-8653	37	5	or	or	CCONJ
easat-8653	37	6	those	those	PRON
easat-8653	37	7	undergoing	undergo	VERB
easat-8653	37	8	concurrent	concurrent	ADJ
easat-8653	37	9	clinical	clinical	ADJ
easat-8653	37	10	trials	trial	NOUN
easat-8653	37	11	were	be	AUX
easat-8653	37	12	excluded	exclude	VERB
easat-8653	37	13	.	.	PUNCT
easat-8653	38	1	data	datum	NOUN
easat-8653	38	2	were	be	AUX
easat-8653	38	3	extracted	extract	VERB
easat-8653	38	4	from	from	ADP
easat-8653	38	5	electronic	electronic	ADJ
easat-8653	38	6	medical	medical	ADJ
easat-8653	38	7	records	record	NOUN
easat-8653	38	8	.	.	PUNCT
easat-8653	39	1	variables	variable	NOUN
easat-8653	39	2	included	include	VERB
easat-8653	39	3	:	:	PUNCT
easat-8653	39	4	cancer	cancer	NOUN
easat-8653	39	5	type	type	NOUN
easat-8653	39	6	,	,	PUNCT
easat-8653	39	7	comorbidities	comorbiditie	NOUN
easat-8653	39	8	,	,	PUNCT
easat-8653	39	9	demographic	demographic	ADJ
easat-8653	39	10	data	datum	NOUN
easat-8653	39	11	(	(	PUNCT
easat-8653	39	12	age	age	NOUN
easat-8653	39	13	,	,	PUNCT
easat-8653	39	14	gender	gender	NOUN
easat-8653	39	15	)	)	PUNCT
easat-8653	39	16	,	,	PUNCT
easat-8653	39	17	and	and	CCONJ
easat-8653	39	18	mortality	mortality	NOUN
easat-8653	39	19	status	status	NOUN
easat-8653	39	20	.	.	PUNCT
easat-8653	40	1	descriptive	descriptive	ADJ
easat-8653	40	2	statistics	statistic	NOUN
easat-8653	40	3	were	be	AUX
easat-8653	40	4	used	use	VERB
easat-8653	40	5	to	to	PART
easat-8653	40	6	summarize	summarize	VERB
easat-8653	40	7	baseline	baseline	NOUN
easat-8653	40	8	characteristics	characteristic	NOUN
easat-8653	40	9	.	.	PUNCT
easat-8653	41	1	the	the	DET
easat-8653	41	2	chi	chi	ADJ
easat-8653	41	3	-	-	PUNCT
easat-8653	41	4	square	square	ADJ
easat-8653	41	5	test	test	NOUN
easat-8653	41	6	assessed	assess	VERB
easat-8653	41	7	associations	association	NOUN
easat-8653	41	8	between	between	ADP
easat-8653	41	9	cancer	cancer	NOUN
easat-8653	41	10	type	type	NOUN
easat-8653	41	11	and	and	CCONJ
easat-8653	41	12	mortality	mortality	NOUN
easat-8653	41	13	.	.	PUNCT
easat-8653	42	1	multivariate	multivariate	NOUN
easat-8653	42	2	logistic	logistic	ADJ
easat-8653	42	3	regression	regression	NOUN
easat-8653	42	4	identified	identify	VERB
easat-8653	42	5	predictors	predictor	NOUN
easat-8653	42	6	of	of	ADP
easat-8653	42	7	mortality	mortality	NOUN
easat-8653	42	8	.	.	PUNCT
easat-8653	43	1	relative	relative	ADJ
easat-8653	43	2	risk	risk	NOUN
easat-8653	43	3	(	(	PUNCT
easat-8653	43	4	rr	rr	NOUN
easat-8653	43	5	)	)	PUNCT
easat-8653	43	6	and	and	CCONJ
easat-8653	43	7	95	95	NUM
easat-8653	43	8	%	%	NOUN
easat-8653	43	9	confidence	confidence	NOUN
easat-8653	43	10	intervals	interval	NOUN
easat-8653	43	11	(	(	PUNCT
easat-8653	43	12	ci	ci	NOUN
easat-8653	43	13	)	)	PUNCT
easat-8653	43	14	were	be	AUX
easat-8653	43	15	calculated	calculate	VERB
easat-8653	43	16	.	.	PUNCT
easat-8653	44	1	a	a	DET
easat-8653	44	2	p	p	NOUN
easat-8653	44	3	-	-	PUNCT
easat-8653	44	4	value	value	NOUN
easat-8653	44	5	<	<	X
easat-8653	44	6	0.05	0.05	NUM
easat-8653	44	7	was	be	AUX
easat-8653	44	8	considered	consider	VERB
easat-8653	44	9	statistically	statistically	ADV
easat-8653	44	10	significant	significant	ADJ
easat-8653	44	11	.	.	PUNCT
easat-8653	45	1	this	this	DET
easat-8653	45	2	study	study	NOUN
easat-8653	45	3	was	be	AUX
easat-8653	45	4	approved	approve	VERB
easat-8653	45	5	by	by	ADP
easat-8653	45	6	the	the	DET
easat-8653	45	7	institutional	institutional	ADJ
easat-8653	45	8	ethics	ethic	NOUN
easat-8653	45	9	committee	committee	PROPN
easat-8653	45	10	of	of	ADP
easat-8653	45	11	dr	dr	PROPN
easat-8653	45	12	.	.	PROPN
easat-8653	45	13	soetomo	soetomo	PROPN
easat-8653	45	14	general	general	ADJ
easat-8653	45	15	hospital	hospital	NOUN
easat-8653	45	16	.	.	PUNCT
easat-8653	46	1	all	all	DET
easat-8653	46	2	patient	patient	ADJ
easat-8653	46	3	data	datum	NOUN
easat-8653	46	4	were	be	AUX
easat-8653	46	5	anonymized	anonymize	VERB
easat-8653	46	6	to	to	PART
easat-8653	46	7	ensure	ensure	VERB
easat-8653	46	8	confidentiality	confidentiality	NOUN
easat-8653	46	9	.	.	PUNCT
easat-8653	47	1	figure	figure	NOUN
easat-8653	47	2	1	1	NUM
easat-8653	47	3	.	.	PUNCT
easat-8653	47	4	research	research	NOUN
easat-8653	47	5	flow	flow	NOUN
easat-8653	47	6	.	.	PUNCT
easat-8653	48	1	531	531	NUM
easat-8653	48	2	edelweiss	edelweiss	PROPN
easat-8653	48	3	applied	apply	VERB
easat-8653	48	4	science	science	NOUN
easat-8653	48	5	and	and	CCONJ
easat-8653	48	6	technology	technology	NOUN
easat-8653	48	7	issn	issn	PROPN
easat-8653	48	8	:	:	PUNCT
easat-8653	48	9	2576	2576	NUM
easat-8653	48	10	-	-	SYM
easat-8653	48	11	8484	8484	NUM
easat-8653	48	12	vol	vol	NOUN
easat-8653	48	13	.	.	PROPN
easat-8653	49	1	9	9	NUM
easat-8653	49	2	,	,	PUNCT
easat-8653	49	3	no	no	INTJ
easat-8653	49	4	.	.	NOUN
easat-8653	49	5	7	7	NUM
easat-8653	49	6	:	:	PUNCT
easat-8653	49	7	529	529	NUM
easat-8653	49	8	-	-	SYM
easat-8653	49	9	535	535	NUM
easat-8653	49	10	,	,	PUNCT
easat-8653	49	11	2025	2025	NUM
easat-8653	49	12	doi	doi	NOUN
easat-8653	49	13	:	:	PUNCT
easat-8653	49	14	10.55214/25768484.v9i7.8653	10.55214/25768484.v9i7.8653	PROPN
easat-8653	49	15	©	©	PROPN
easat-8653	49	16	2025	2025	NUM
easat-8653	49	17	by	by	ADP
easat-8653	49	18	the	the	DET
easat-8653	49	19	authors	author	NOUN
easat-8653	49	20	;	;	PUNCT
easat-8653	49	21	licensee	licensee	PROPN
easat-8653	49	22	learning	learning	NOUN
easat-8653	49	23	gate	gate	NOUN
easat-8653	49	24	3	3	PROPN
easat-8653	49	25	.	.	PROPN
easat-8653	49	26	results	result	VERB
easat-8653	49	27	a	a	DET
easat-8653	49	28	total	total	NOUN
easat-8653	49	29	of	of	ADP
easat-8653	49	30	237	237	NUM
easat-8653	49	31	patients	patient	NOUN
easat-8653	49	32	met	meet	VERB
easat-8653	49	33	the	the	DET
easat-8653	49	34	inclusion	inclusion	NOUN
easat-8653	49	35	criteria	criterion	NOUN
easat-8653	49	36	.	.	PUNCT
easat-8653	50	1	among	among	ADP
easat-8653	50	2	them	they	PRON
easat-8653	50	3	,	,	PUNCT
easat-8653	50	4	185	185	NUM
easat-8653	50	5	(	(	PUNCT
easat-8653	50	6	78	78	NUM
easat-8653	50	7	%	%	NOUN
easat-8653	50	8	)	)	PUNCT
easat-8653	50	9	had	have	VERB
easat-8653	50	10	solid	solid	ADJ
easat-8653	50	11	tumors	tumor	NOUN
easat-8653	50	12	,	,	PUNCT
easat-8653	50	13	while	while	SCONJ
easat-8653	50	14	52	52	NUM
easat-8653	50	15	(	(	PUNCT
easat-8653	50	16	22	22	NUM
easat-8653	50	17	%	%	NOUN
easat-8653	50	18	)	)	PUNCT
easat-8653	50	19	had	have	VERB
easat-8653	50	20	hematological	hematological	ADJ
easat-8653	50	21	malignancies	malignancy	NOUN
easat-8653	50	22	.	.	PUNCT
easat-8653	51	1	the	the	DET
easat-8653	51	2	cohort	cohort	NOUN
easat-8653	51	3	had	have	VERB
easat-8653	51	4	a	a	DET
easat-8653	51	5	slight	slight	ADJ
easat-8653	51	6	male	male	ADJ
easat-8653	51	7	predominance	predominance	NOUN
easat-8653	51	8	,	,	PUNCT
easat-8653	51	9	and	and	CCONJ
easat-8653	51	10	the	the	DET
easat-8653	51	11	majority	majority	NOUN
easat-8653	51	12	of	of	ADP
easat-8653	51	13	patients	patient	NOUN
easat-8653	51	14	presented	present	VERB
easat-8653	51	15	with	with	ADP
easat-8653	51	16	at	at	ADV
easat-8653	51	17	least	least	ADV
easat-8653	51	18	one	one	NUM
easat-8653	51	19	comorbid	comorbid	NOUN
easat-8653	51	20	condition	condition	NOUN
easat-8653	51	21	(	(	PUNCT
easat-8653	51	22	n	n	NOUN
easat-8653	51	23	=	=	SYM
easat-8653	51	24	177	177	NUM
easat-8653	51	25	,	,	PUNCT
easat-8653	51	26	74.7	74.7	NUM
easat-8653	51	27	%	%	NOUN
easat-8653	51	28	)	)	PUNCT
easat-8653	51	29	.	.	PUNCT
easat-8653	52	1	table	table	NOUN
easat-8653	52	2	1	1	NUM
easat-8653	52	3	.	.	PUNCT
easat-8653	52	4	subject	subject	ADJ
easat-8653	52	5	characteristic	characteristic	ADJ
easat-8653	52	6	distribution	distribution	NOUN
easat-8653	52	7	.	.	PUNCT
easat-8653	53	1	variable	variable	ADJ
easat-8653	53	2	total	total	NOUN
easat-8653	53	3	,	,	PUNCT
easat-8653	53	4	n	n	PROPN
easat-8653	53	5	(	(	PUNCT
easat-8653	53	6	%	%	INTJ
easat-8653	53	7	)	)	PUNCT
easat-8653	53	8	solid	solid	ADJ
easat-8653	53	9	cancer	cancer	NOUN
easat-8653	53	10	185	185	NUM
easat-8653	53	11	(	(	PUNCT
easat-8653	53	12	78	78	NUM
easat-8653	53	13	%	%	NOUN
easat-8653	53	14	)	)	PUNCT
easat-8653	53	15	sex	sex	NOUN
easat-8653	53	16	male	male	NOUN
easat-8653	53	17	79	79	NUM
easat-8653	53	18	(	(	PUNCT
easat-8653	53	19	33.3	33.3	NUM
easat-8653	53	20	%	%	NOUN
easat-8653	53	21	)	)	PUNCT
easat-8653	53	22	female	female	NOUN
easat-8653	53	23	106	106	NUM
easat-8653	53	24	(	(	PUNCT
easat-8653	53	25	44.7	44.7	NUM
easat-8653	53	26	%	%	NOUN
easat-8653	53	27	)	)	PUNCT
easat-8653	53	28	comorbidities	comorbiditie	NOUN
easat-8653	53	29	with	with	ADP
easat-8653	53	30	comorbidities	comorbiditie	NOUN
easat-8653	53	31	139	139	NUM
easat-8653	53	32	(	(	PUNCT
easat-8653	53	33	58.7	58.7	NUM
easat-8653	53	34	%	%	NOUN
easat-8653	53	35	)	)	PUNCT
easat-8653	53	36	without	without	ADP
easat-8653	53	37	comorbidities	comorbiditie	NOUN
easat-8653	53	38	46	46	NUM
easat-8653	53	39	(	(	PUNCT
easat-8653	53	40	19.3	19.3	NUM
easat-8653	53	41	%	%	NOUN
easat-8653	53	42	)	)	PUNCT
easat-8653	53	43	mortality	mortality	NOUN
easat-8653	53	44	survived	survive	VERB
easat-8653	53	45	123	123	NUM
easat-8653	53	46	(	(	PUNCT
easat-8653	53	47	52	52	NUM
easat-8653	53	48	%	%	NOUN
easat-8653	53	49	)	)	PUNCT
easat-8653	53	50	deceased	decease	VERB
easat-8653	53	51	62	62	NUM
easat-8653	53	52	(	(	PUNCT
easat-8653	53	53	26	26	NUM
easat-8653	53	54	%	%	NOUN
easat-8653	53	55	)	)	PUNCT
easat-8653	53	56	hematologic	hematologic	NOUN
easat-8653	53	57	cancer	cancer	NOUN
easat-8653	53	58	52	52	NUM
easat-8653	53	59	(	(	PUNCT
easat-8653	53	60	22	22	NUM
easat-8653	53	61	%	%	NOUN
easat-8653	53	62	)	)	PUNCT
easat-8653	53	63	sex	sex	NOUN
easat-8653	53	64	male	male	NOUN
easat-8653	53	65	20	20	NUM
easat-8653	53	66	(	(	PUNCT
easat-8653	53	67	8.5	8.5	NUM
easat-8653	53	68	%	%	NOUN
easat-8653	53	69	)	)	PUNCT
easat-8653	53	70	female	female	NOUN
easat-8653	53	71	32	32	NUM
easat-8653	53	72	(	(	PUNCT
easat-8653	53	73	13.5	13.5	NUM
easat-8653	53	74	%	%	NOUN
easat-8653	53	75	)	)	PUNCT
easat-8653	53	76	comorbidities	comorbiditie	NOUN
easat-8653	53	77	with	with	ADP
easat-8653	53	78	comorbidities	comorbiditie	NOUN
easat-8653	53	79	38	38	NUM
easat-8653	53	80	(	(	PUNCT
easat-8653	53	81	16	16	NUM
easat-8653	53	82	%	%	NOUN
easat-8653	53	83	)	)	PUNCT
easat-8653	53	84	without	without	ADP
easat-8653	53	85	comorbidities	comorbiditie	NOUN
easat-8653	53	86	14	14	NUM
easat-8653	53	87	(	(	PUNCT
easat-8653	53	88	6	6	NUM
easat-8653	53	89	%	%	NOUN
easat-8653	53	90	)	)	PUNCT
easat-8653	53	91	mortality	mortality	NOUN
easat-8653	53	92	survived	survive	VERB
easat-8653	53	93	39	39	NUM
easat-8653	53	94	(	(	PUNCT
easat-8653	53	95	16	16	NUM
easat-8653	53	96	%	%	NOUN
easat-8653	53	97	)	)	PUNCT
easat-8653	53	98	deceased	decease	VERB
easat-8653	53	99	13	13	NUM
easat-8653	53	100	(	(	PUNCT
easat-8653	53	101	6	6	NUM
easat-8653	53	102	%	%	NOUN
easat-8653	53	103	)	)	PUNCT
easat-8653	54	1	there	there	PRON
easat-8653	54	2	was	be	VERB
easat-8653	54	3	no	no	DET
easat-8653	54	4	statistically	statistically	ADV
easat-8653	54	5	significant	significant	ADJ
easat-8653	54	6	difference	difference	NOUN
easat-8653	54	7	in	in	ADP
easat-8653	54	8	mortality	mortality	NOUN
easat-8653	54	9	between	between	ADP
easat-8653	54	10	solid	solid	ADJ
easat-8653	54	11	and	and	CCONJ
easat-8653	54	12	hematological	hematological	ADJ
easat-8653	54	13	cancer	cancer	NOUN
easat-8653	54	14	types	type	NOUN
easat-8653	54	15	(	(	PUNCT
easat-8653	54	16	p	p	X
easat-8653	54	17	>	>	X
easat-8653	54	18	0.05	0.05	NUM
easat-8653	54	19	)	)	PUNCT
easat-8653	54	20	.	.	PUNCT
easat-8653	55	1	however	however	ADV
easat-8653	55	2	,	,	PUNCT
easat-8653	55	3	bivariate	bivariate	ADJ
easat-8653	55	4	analysis	analysis	NOUN
easat-8653	55	5	revealed	reveal	VERB
easat-8653	55	6	a	a	DET
easat-8653	55	7	significant	significant	ADJ
easat-8653	55	8	association	association	NOUN
easat-8653	55	9	between	between	ADP
easat-8653	55	10	the	the	DET
easat-8653	55	11	presence	presence	NOUN
easat-8653	55	12	of	of	ADP
easat-8653	55	13	comorbidities	comorbiditie	NOUN
easat-8653	55	14	and	and	CCONJ
easat-8653	55	15	increased	increase	VERB
easat-8653	55	16	mortality	mortality	NOUN
easat-8653	55	17	(	(	PUNCT
easat-8653	55	18	p	p	X
easat-8653	55	19	<	<	X
easat-8653	55	20	0.001	0.001	NUM
easat-8653	55	21	)	)	PUNCT
easat-8653	55	22	.	.	PUNCT
easat-8653	56	1	532	532	NUM
easat-8653	56	2	edelweiss	edelweiss	PROPN
easat-8653	56	3	applied	apply	VERB
easat-8653	56	4	science	science	NOUN
easat-8653	56	5	and	and	CCONJ
easat-8653	56	6	technology	technology	NOUN
easat-8653	56	7	issn	issn	PROPN
easat-8653	56	8	:	:	PUNCT
easat-8653	56	9	2576	2576	NUM
easat-8653	56	10	-	-	SYM
easat-8653	56	11	8484	8484	NUM
easat-8653	56	12	vol	vol	NOUN
easat-8653	56	13	.	.	PROPN
easat-8653	57	1	9	9	NUM
easat-8653	57	2	,	,	PUNCT
easat-8653	57	3	no	no	INTJ
easat-8653	57	4	.	.	NOUN
easat-8653	57	5	7	7	NUM
easat-8653	57	6	:	:	PUNCT
easat-8653	57	7	529	529	NUM
easat-8653	57	8	-	-	SYM
easat-8653	57	9	535	535	NUM
easat-8653	57	10	,	,	PUNCT
easat-8653	57	11	2025	2025	NUM
easat-8653	57	12	doi	doi	NOUN
easat-8653	57	13	:	:	PUNCT
easat-8653	57	14	10.55214/25768484.v9i7.8653	10.55214/25768484.v9i7.8653	PROPN
easat-8653	57	15	©	©	PROPN
easat-8653	57	16	2025	2025	NUM
easat-8653	57	17	by	by	ADP
easat-8653	57	18	the	the	DET
easat-8653	57	19	authors	author	NOUN
easat-8653	57	20	;	;	PUNCT
easat-8653	57	21	licensee	licensee	PROPN
easat-8653	57	22	learning	learn	VERB
easat-8653	57	23	gate	gate	NOUN
easat-8653	57	24	figure	figure	NOUN
easat-8653	57	25	2	2	NUM
easat-8653	57	26	.	.	PUNCT
easat-8653	57	27	distribution	distribution	NOUN
easat-8653	57	28	pie	pie	NOUN
easat-8653	57	29	chart	chart	NOUN
easat-8653	57	30	of	of	ADP
easat-8653	57	31	number	number	NOUN
easat-8653	57	32	of	of	ADP
easat-8653	57	33	deceased	deceased	ADJ
easat-8653	57	34	patients	patient	NOUN
easat-8653	57	35	based	base	VERB
easat-8653	57	36	on	on	ADP
easat-8653	57	37	comorbidities	comorbiditie	NOUN
easat-8653	57	38	.	.	PUNCT
easat-8653	58	1	as	as	SCONJ
easat-8653	58	2	shown	show	VERB
easat-8653	58	3	in	in	ADP
easat-8653	58	4	figure	figure	NOUN
easat-8653	58	5	2	2	NUM
easat-8653	58	6	.	.	NUM
easat-8653	58	7	,	,	PUNCT
easat-8653	58	8	patients	patient	NOUN
easat-8653	58	9	with	with	ADP
easat-8653	58	10	two	two	NUM
easat-8653	58	11	comorbidities	comorbiditie	NOUN
easat-8653	58	12	had	have	VERB
easat-8653	58	13	the	the	DET
easat-8653	58	14	highest	high	ADJ
easat-8653	58	15	mortality	mortality	NOUN
easat-8653	58	16	among	among	ADP
easat-8653	58	17	the	the	DET
easat-8653	58	18	177	177	NUM
easat-8653	58	19	patients	patient	NOUN
easat-8653	58	20	with	with	ADP
easat-8653	58	21	comorbid	comorbid	NOUN
easat-8653	58	22	conditions	condition	NOUN
easat-8653	58	23	(	(	PUNCT
easat-8653	58	24	33	33	NUM
easat-8653	58	25	patients	patient	NOUN
easat-8653	58	26	,	,	PUNCT
easat-8653	58	27	18.6	18.6	NUM
easat-8653	58	28	%	%	NOUN
easat-8653	58	29	)	)	PUNCT
easat-8653	58	30	,	,	PUNCT
easat-8653	58	31	followed	follow	VERB
easat-8653	58	32	by	by	ADP
easat-8653	58	33	those	those	PRON
easat-8653	58	34	with	with	ADP
easat-8653	58	35	three	three	NUM
easat-8653	58	36	comorbidities	comorbiditie	NOUN
easat-8653	58	37	(	(	PUNCT
easat-8653	58	38	28	28	NUM
easat-8653	58	39	patients	patient	NOUN
easat-8653	58	40	,	,	PUNCT
easat-8653	58	41	15.8	15.8	NUM
easat-8653	58	42	%	%	NOUN
easat-8653	58	43	)	)	PUNCT
easat-8653	58	44	.	.	PUNCT
easat-8653	59	1	mortality	mortality	NOUN
easat-8653	59	2	was	be	AUX
easat-8653	59	3	also	also	ADV
easat-8653	59	4	observed	observe	VERB
easat-8653	59	5	in	in	ADP
easat-8653	59	6	patients	patient	NOUN
easat-8653	59	7	with	with	ADP
easat-8653	59	8	four	four	NUM
easat-8653	59	9	comorbidities	comorbiditie	NOUN
easat-8653	59	10	(	(	PUNCT
easat-8653	59	11	7	7	NUM
easat-8653	59	12	patients	patient	NOUN
easat-8653	59	13	,	,	PUNCT
easat-8653	59	14	4	4	NUM
easat-8653	59	15	%	%	NOUN
easat-8653	59	16	)	)	PUNCT
easat-8653	59	17	,	,	PUNCT
easat-8653	59	18	one	one	NUM
easat-8653	59	19	comorbidity	comorbidity	NOUN
easat-8653	59	20	(	(	PUNCT
easat-8653	59	21	4	4	NUM
easat-8653	59	22	patients	patient	NOUN
easat-8653	59	23	,	,	PUNCT
easat-8653	59	24	2.3	2.3	NUM
easat-8653	59	25	%	%	NOUN
easat-8653	59	26	)	)	PUNCT
easat-8653	59	27	,	,	PUNCT
easat-8653	59	28	and	and	CCONJ
easat-8653	59	29	all	all	DET
easat-8653	59	30	patients	patient	NOUN
easat-8653	59	31	with	with	ADP
easat-8653	59	32	five	five	NUM
easat-8653	59	33	comorbidities	comorbiditie	NOUN
easat-8653	59	34	(	(	PUNCT
easat-8653	59	35	2	2	NUM
easat-8653	59	36	patients	patient	NOUN
easat-8653	59	37	,	,	PUNCT
easat-8653	59	38	1.1	1.1	NUM
easat-8653	59	39	%	%	NOUN
easat-8653	59	40	)	)	PUNCT
easat-8653	59	41	.	.	PUNCT
easat-8653	60	1	533	533	NUM
easat-8653	60	2	edelweiss	edelweiss	PROPN
easat-8653	60	3	applied	apply	VERB
easat-8653	60	4	science	science	NOUN
easat-8653	60	5	and	and	CCONJ
easat-8653	60	6	technology	technology	NOUN
easat-8653	60	7	issn	issn	PROPN
easat-8653	60	8	:	:	PUNCT
easat-8653	60	9	2576	2576	NUM
easat-8653	60	10	-	-	SYM
easat-8653	60	11	8484	8484	NUM
easat-8653	60	12	vol	vol	NOUN
easat-8653	60	13	.	.	PROPN
easat-8653	61	1	9	9	NUM
easat-8653	61	2	,	,	PUNCT
easat-8653	61	3	no	no	INTJ
easat-8653	61	4	.	.	NOUN
easat-8653	61	5	7	7	NUM
easat-8653	61	6	:	:	PUNCT
easat-8653	61	7	529	529	NUM
easat-8653	61	8	-	-	SYM
easat-8653	61	9	535	535	NUM
easat-8653	61	10	,	,	PUNCT
easat-8653	61	11	2025	2025	NUM
easat-8653	61	12	doi	doi	NOUN
easat-8653	61	13	:	:	PUNCT
easat-8653	61	14	10.55214/25768484.v9i7.8653	10.55214/25768484.v9i7.8653	PROPN
easat-8653	61	15	©	©	PROPN
easat-8653	61	16	2025	2025	NUM
easat-8653	61	17	by	by	ADP
easat-8653	61	18	the	the	DET
easat-8653	61	19	authors	author	NOUN
easat-8653	61	20	;	;	PUNCT
easat-8653	61	21	licensee	licensee	PROPN
easat-8653	61	22	learning	learn	VERB
easat-8653	61	23	gate	gate	PROPN
easat-8653	61	24	figure	figure	NOUN
easat-8653	61	25	3	3	NUM
easat-8653	61	26	.	.	PUNCT
easat-8653	61	27	distribution	distribution	NOUN
easat-8653	61	28	pie	pie	NOUN
easat-8653	61	29	chart	chart	NOUN
easat-8653	61	30	of	of	ADP
easat-8653	61	31	comorbidity	comorbidity	NOUN
easat-8653	61	32	combinations	combination	NOUN
easat-8653	61	33	in	in	ADP
easat-8653	61	34	the	the	DET
easat-8653	61	35	patient	patient	NOUN
easat-8653	61	36	group	group	NOUN
easat-8653	61	37	with	with	ADP
easat-8653	61	38	the	the	DET
easat-8653	61	39	highest	high	ADJ
easat-8653	61	40	mortality	mortality	NOUN
easat-8653	61	41	among	among	ADP
easat-8653	61	42	those	those	PRON
easat-8653	61	43	with	with	ADP
easat-8653	61	44	two	two	NUM
easat-8653	61	45	comorbidities	comorbiditie	NOUN
easat-8653	61	46	.	.	PUNCT
easat-8653	62	1	figure	figure	NOUN
easat-8653	62	2	3	3	NUM
easat-8653	62	3	.	.	PUNCT
easat-8653	62	4	shows	show	VERB
easat-8653	62	5	that	that	SCONJ
easat-8653	62	6	among	among	ADP
easat-8653	62	7	the	the	DET
easat-8653	62	8	33	33	NUM
easat-8653	62	9	patients	patient	NOUN
easat-8653	62	10	with	with	ADP
easat-8653	62	11	two	two	NUM
easat-8653	62	12	comorbidities	comorbiditie	NOUN
easat-8653	62	13	,	,	PUNCT
easat-8653	62	14	the	the	DET
easat-8653	62	15	most	most	ADV
easat-8653	62	16	frequent	frequent	ADJ
easat-8653	62	17	combination	combination	NOUN
easat-8653	62	18	was	be	AUX
easat-8653	62	19	metabolic	metabolic	ADJ
easat-8653	62	20	disorder	disorder	NOUN
easat-8653	62	21	and	and	CCONJ
easat-8653	62	22	coagulopathy	coagulopathy	ADJ
easat-8653	62	23	(	(	PUNCT
easat-8653	62	24	7	7	NUM
easat-8653	62	25	patients	patient	NOUN
easat-8653	62	26	,	,	PUNCT
easat-8653	62	27	21.2	21.2	NUM
easat-8653	62	28	%	%	NOUN
easat-8653	62	29	)	)	PUNCT
easat-8653	62	30	,	,	PUNCT
easat-8653	62	31	followed	follow	VERB
easat-8653	62	32	by	by	ADP
easat-8653	62	33	metabolic	metabolic	NOUN
easat-8653	62	34	disorder	disorder	NOUN
easat-8653	62	35	with	with	ADP
easat-8653	62	36	neoplastic	neoplastic	ADJ
easat-8653	62	37	anemia	anemia	NOUN
easat-8653	62	38	(	(	PUNCT
easat-8653	62	39	4	4	NUM
easat-8653	62	40	patients	patient	NOUN
easat-8653	62	41	,	,	PUNCT
easat-8653	62	42	12.1	12.1	NUM
easat-8653	62	43	%	%	NOUN
easat-8653	62	44	)	)	PUNCT
easat-8653	62	45	.	.	PUNCT
easat-8653	63	1	metabolic	metabolic	NOUN
easat-8653	63	2	disorder	disorder	NOUN
easat-8653	63	3	combined	combine	VERB
easat-8653	63	4	with	with	ADP
easat-8653	63	5	either	either	PRON
easat-8653	63	6	diabetes	diabete	NOUN
easat-8653	63	7	mellitus	mellitus	NOUN
easat-8653	63	8	or	or	CCONJ
easat-8653	63	9	acute	acute	ADJ
easat-8653	63	10	respiratory	respiratory	ADJ
easat-8653	63	11	failure	failure	NOUN
easat-8653	63	12	was	be	AUX
easat-8653	63	13	observed	observe	VERB
easat-8653	63	14	in	in	ADP
easat-8653	63	15	3	3	NUM
easat-8653	63	16	patients	patient	NOUN
easat-8653	63	17	each	each	PRON
easat-8653	63	18	(	(	PUNCT
easat-8653	63	19	9.1	9.1	NUM
easat-8653	63	20	%	%	NOUN
easat-8653	63	21	)	)	PUNCT
easat-8653	63	22	.	.	PUNCT
easat-8653	64	1	combinations	combination	NOUN
easat-8653	64	2	of	of	ADP
easat-8653	64	3	diabetes	diabetes	NOUN
easat-8653	64	4	mellitus	mellitus	NOUN
easat-8653	64	5	with	with	ADP
easat-8653	64	6	coagulopathy	coagulopathy	ADJ
easat-8653	64	7	and	and	CCONJ
easat-8653	64	8	neoplastic	neoplastic	ADJ
easat-8653	64	9	anemia	anemia	NOUN
easat-8653	64	10	with	with	ADP
easat-8653	64	11	hypokalemia	hypokalemia	PROPN
easat-8653	64	12	were	be	AUX
easat-8653	64	13	each	each	PRON
easat-8653	64	14	found	find	VERB
easat-8653	64	15	in	in	ADP
easat-8653	64	16	2	2	NUM
easat-8653	64	17	patients	patient	NOUN
easat-8653	64	18	(	(	PUNCT
easat-8653	64	19	6.1	6.1	NUM
easat-8653	64	20	%	%	NOUN
easat-8653	64	21	)	)	PUNCT
easat-8653	64	22	,	,	PUNCT
easat-8653	64	23	while	while	SCONJ
easat-8653	64	24	the	the	DET
easat-8653	64	25	remaining	remain	VERB
easat-8653	64	26	combinations	combination	NOUN
easat-8653	64	27	were	be	AUX
easat-8653	64	28	observed	observe	VERB
easat-8653	64	29	in	in	ADP
easat-8653	64	30	1	1	NUM
easat-8653	64	31	patient	patient	NOUN
easat-8653	64	32	each	each	PRON
easat-8653	64	33	(	(	PUNCT
easat-8653	64	34	3	3	NUM
easat-8653	64	35	%	%	NOUN
easat-8653	64	36	)	)	PUNCT
easat-8653	64	37	.	.	PUNCT
easat-8653	65	1	table	table	NOUN
easat-8653	65	2	2	2	NUM
easat-8653	65	3	.	.	PUNCT
easat-8653	65	4	bivariate	bivariate	ADJ
easat-8653	65	5	analysis	analysis	NOUN
easat-8653	65	6	results	result	NOUN
easat-8653	65	7	of	of	ADP
easat-8653	65	8	independent	independent	ADJ
easat-8653	65	9	variables	variable	NOUN
easat-8653	65	10	.	.	PUNCT
easat-8653	66	1	variable	variable	ADJ
easat-8653	66	2	mortality	mortality	NOUN
easat-8653	66	3	rate	rate	NOUN
easat-8653	66	4	deceased	decease	VERB
easat-8653	66	5	n	n	PROPN
easat-8653	66	6	(	(	PUNCT
easat-8653	66	7	%	%	INTJ
easat-8653	66	8	)	)	PUNCT
easat-8653	66	9	survived	survive	VERB
easat-8653	66	10	n	n	PROPN
easat-8653	66	11	(	(	PUNCT
easat-8653	66	12	%	%	INTJ
easat-8653	66	13	)	)	PUNCT
easat-8653	66	14	total	total	NOUN
easat-8653	66	15	(	(	PUNCT
easat-8653	66	16	n	n	CCONJ
easat-8653	66	17	)	)	PUNCT
easat-8653	66	18	p	p	ADJ
easat-8653	66	19	-	-	PUNCT
easat-8653	66	20	value	value	NOUN
easat-8653	66	21	male	male	NOUN
easat-8653	66	22	32	32	NUM
easat-8653	66	23	(	(	PUNCT
easat-8653	66	24	32.3	32.3	NUM
easat-8653	66	25	%	%	NOUN
easat-8653	66	26	)	)	PUNCT
easat-8653	66	27	67	67	NUM
easat-8653	66	28	(	(	PUNCT
easat-8653	66	29	67.7	67.7	NUM
easat-8653	66	30	%	%	NOUN
easat-8653	66	31	)	)	PUNCT
easat-8653	66	32	99	99	NUM
easat-8653	66	33	0.849	0.849	NUM
easat-8653	66	34	female	female	ADJ
easat-8653	66	35	43	43	NUM
easat-8653	66	36	(	(	PUNCT
easat-8653	66	37	31.2	31.2	NUM
easat-8653	66	38	%	%	NOUN
easat-8653	66	39	)	)	PUNCT
easat-8653	66	40	95	95	NUM
easat-8653	66	41	(	(	PUNCT
easat-8653	66	42	68.8	68.8	NUM
easat-8653	66	43	%	%	NOUN
easat-8653	66	44	)	)	PUNCT
easat-8653	66	45	138	138	NUM
easat-8653	67	1	solid	solid	ADJ
easat-8653	67	2	62	62	NUM
easat-8653	67	3	(	(	PUNCT
easat-8653	67	4	33.5	33.5	NUM
easat-8653	67	5	%	%	NOUN
easat-8653	67	6	)	)	PUNCT
easat-8653	67	7	123	123	NUM
easat-8653	67	8	(	(	PUNCT
easat-8653	67	9	66.5	66.5	NUM
easat-8653	67	10	%	%	NOUN
easat-8653	67	11	)	)	PUNCT
easat-8653	67	12	185	185	NUM
easat-8653	67	13	0.244	0.244	NUM
easat-8653	67	14	non	non	ADJ
easat-8653	67	15	-	-	ADJ
easat-8653	67	16	solid	solid	ADJ
easat-8653	67	17	/	/	SYM
easat-8653	67	18	hematologic	hematologic	NOUN
easat-8653	67	19	13	13	NUM
easat-8653	67	20	(	(	PUNCT
easat-8653	67	21	25.0	25.0	NUM
easat-8653	67	22	%	%	NOUN
easat-8653	67	23	)	)	PUNCT
easat-8653	67	24	39	39	NUM
easat-8653	67	25	(	(	PUNCT
easat-8653	67	26	75.0	75.0	NUM
easat-8653	67	27	%	%	NOUN
easat-8653	67	28	)	)	PUNCT
easat-8653	67	29	52	52	NUM
easat-8653	67	30	with	with	ADP
easat-8653	67	31	comorbidities	comorbiditie	NOUN
easat-8653	67	32	74	74	NUM
easat-8653	67	33	(	(	PUNCT
easat-8653	67	34	41.8	41.8	NUM
easat-8653	67	35	%	%	NOUN
easat-8653	67	36	)	)	PUNCT
easat-8653	67	37	103	103	NUM
easat-8653	67	38	(	(	PUNCT
easat-8653	67	39	58.2	58.2	NUM
easat-8653	67	40	%	%	NOUN
easat-8653	67	41	)	)	PUNCT
easat-8653	67	42	177	177	NUM
easat-8653	67	43	0.000	0.000	NUM
easat-8653	67	44	without	without	ADP
easat-8653	67	45	comorbidities	comorbiditie	NOUN
easat-8653	67	46	1	1	NUM
easat-8653	67	47	(	(	PUNCT
easat-8653	67	48	1.7	1.7	NUM
easat-8653	67	49	%	%	NOUN
easat-8653	67	50	)	)	PUNCT
easat-8653	67	51	59	59	NUM
easat-8653	67	52	(	(	PUNCT
easat-8653	67	53	98.3	98.3	NUM
easat-8653	67	54	%	%	NOUN
easat-8653	67	55	)	)	PUNCT
easat-8653	67	56	60	60	NUM
easat-8653	67	57	total	total	NOUN
easat-8653	67	58	75	75	NUM
easat-8653	67	59	(	(	PUNCT
easat-8653	67	60	31.6	31.6	NUM
easat-8653	67	61	%	%	NOUN
easat-8653	67	62	)	)	PUNCT
easat-8653	67	63	162	162	NUM
easat-8653	67	64	(	(	PUNCT
easat-8653	67	65	68.4	68.4	NUM
easat-8653	67	66	%	%	NOUN
easat-8653	67	67	)	)	PUNCT
easat-8653	67	68	237	237	NUM
easat-8653	67	69	comorbidities	comorbiditie	NOUN
easat-8653	67	70	emerged	emerge	VERB
easat-8653	67	71	as	as	ADP
easat-8653	67	72	the	the	DET
easat-8653	67	73	strongest	strong	ADJ
easat-8653	67	74	independent	independent	ADJ
easat-8653	67	75	predictor	predictor	NOUN
easat-8653	67	76	of	of	ADP
easat-8653	67	77	mortality	mortality	NOUN
easat-8653	67	78	post	post	ADJ
easat-8653	67	79	-	-	ADJ
easat-8653	67	80	covid-19	covid-19	ADJ
easat-8653	67	81	treatment	treatment	NOUN
easat-8653	67	82	(	(	PUNCT
easat-8653	67	83	p	p	X
easat-8653	67	84	<	<	X
easat-8653	67	85	0.001	0.001	NUM
easat-8653	67	86	;	;	PUNCT
easat-8653	67	87	rr	rr	NOUN
easat-8653	67	88	=	=	PROPN
easat-8653	67	89	25.08	25.08	NUM
easat-8653	67	90	;	;	PUNCT
easat-8653	67	91	95	95	NUM
easat-8653	67	92	%	%	NOUN
easat-8653	67	93	ci	ci	NOUN
easat-8653	67	94	:	:	PUNCT
easat-8653	67	95	3.56–176.55	3.56–176.55	NUM
easat-8653	67	96	)	)	PUNCT
easat-8653	67	97	.	.	PUNCT
easat-8653	68	1	other	other	ADJ
easat-8653	68	2	variables	variable	NOUN
easat-8653	68	3	,	,	PUNCT
easat-8653	68	4	including	include	VERB
easat-8653	68	5	cancer	cancer	NOUN
easat-8653	68	6	type	type	NOUN
easat-8653	68	7	and	and	CCONJ
easat-8653	68	8	gender	gender	NOUN
easat-8653	68	9	,	,	PUNCT
easat-8653	68	10	did	do	AUX
easat-8653	68	11	not	not	PART
easat-8653	68	12	reach	reach	VERB
easat-8653	68	13	statistical	statistical	ADJ
easat-8653	68	14	significance	significance	NOUN
easat-8653	68	15	in	in	ADP
easat-8653	68	16	the	the	DET
easat-8653	68	17	multivariate	multivariate	NOUN
easat-8653	68	18	model	model	NOUN
easat-8653	68	19	.	.	PUNCT
easat-8653	69	1	534	534	NUM
easat-8653	69	2	edelweiss	edelweiss	PROPN
easat-8653	69	3	applied	apply	VERB
easat-8653	69	4	science	science	NOUN
easat-8653	69	5	and	and	CCONJ
easat-8653	69	6	technology	technology	NOUN
easat-8653	69	7	issn	issn	PROPN
easat-8653	69	8	:	:	PUNCT
easat-8653	69	9	2576	2576	NUM
easat-8653	69	10	-	-	SYM
easat-8653	69	11	8484	8484	NUM
easat-8653	69	12	vol	vol	NOUN
easat-8653	69	13	.	.	PROPN
easat-8653	70	1	9	9	NUM
easat-8653	70	2	,	,	PUNCT
easat-8653	70	3	no	no	INTJ
easat-8653	70	4	.	.	NOUN
easat-8653	70	5	7	7	NUM
easat-8653	70	6	:	:	PUNCT
easat-8653	70	7	529	529	NUM
easat-8653	70	8	-	-	SYM
easat-8653	70	9	535	535	NUM
easat-8653	70	10	,	,	PUNCT
easat-8653	70	11	2025	2025	NUM
easat-8653	70	12	doi	doi	NOUN
easat-8653	70	13	:	:	PUNCT
easat-8653	70	14	10.55214/25768484.v9i7.8653	10.55214/25768484.v9i7.8653	PROPN
easat-8653	70	15	©	©	PROPN
easat-8653	70	16	2025	2025	NUM
easat-8653	70	17	by	by	ADP
easat-8653	70	18	the	the	DET
easat-8653	70	19	authors	author	NOUN
easat-8653	70	20	;	;	PUNCT
easat-8653	70	21	licensee	licensee	PROPN
easat-8653	70	22	learning	learn	VERB
easat-8653	70	23	gate	gate	NOUN
easat-8653	70	24	table	table	NOUN
easat-8653	70	25	3	3	NUM
easat-8653	70	26	.	.	PUNCT
easat-8653	70	27	relative	relative	ADJ
easat-8653	70	28	risk	risk	NOUN
easat-8653	70	29	(	(	PUNCT
easat-8653	70	30	rr	rr	NOUN
easat-8653	70	31	)	)	PUNCT
easat-8653	70	32	values	value	NOUN
easat-8653	70	33	of	of	ADP
easat-8653	70	34	independent	independent	ADJ
easat-8653	70	35	variables	variable	NOUN
easat-8653	70	36	.	.	PUNCT
easat-8653	71	1	variable	variable	ADJ
easat-8653	71	2	mortality	mortality	NOUN
easat-8653	71	3	rate	rate	NOUN
easat-8653	71	4	relative	relative	ADJ
easat-8653	71	5	risk	risk	NOUN
easat-8653	71	6	(	(	PUNCT
easat-8653	71	7	95	95	NUM
easat-8653	71	8	%	%	NOUN
easat-8653	71	9	ci	ci	NOUN
easat-8653	71	10	)	)	PUNCT
easat-8653	71	11	deceased	decease	VERB
easat-8653	71	12	n	n	PROPN
easat-8653	71	13	(	(	PUNCT
easat-8653	71	14	%	%	INTJ
easat-8653	71	15	)	)	PUNCT
easat-8653	71	16	survived	survive	VERB
easat-8653	71	17	n	n	PROPN
easat-8653	71	18	(	(	PUNCT
easat-8653	71	19	%	%	INTJ
easat-8653	71	20	)	)	PUNCT
easat-8653	71	21	total	total	NOUN
easat-8653	71	22	(	(	PUNCT
easat-8653	71	23	n	n	CCONJ
easat-8653	71	24	)	)	PUNCT
easat-8653	71	25	male	male	NOUN
easat-8653	71	26	32	32	NUM
easat-8653	71	27	(	(	PUNCT
easat-8653	71	28	32.3	32.3	NUM
easat-8653	71	29	%	%	NOUN
easat-8653	71	30	)	)	PUNCT
easat-8653	71	31	67	67	NUM
easat-8653	71	32	(	(	PUNCT
easat-8653	71	33	67.7	67.7	NUM
easat-8653	71	34	%	%	NOUN
easat-8653	71	35	)	)	PUNCT
easat-8653	71	36	99	99	NUM
easat-8653	71	37	1.04	1.04	NUM
easat-8653	71	38	(	(	PUNCT
easat-8653	71	39	95	95	NUM
easat-8653	71	40	%	%	NOUN
easat-8653	71	41	ci	ci	NOUN
easat-8653	71	42	:	:	PUNCT
easat-8653	71	43	0.71	0.71	NUM
easat-8653	71	44	–	–	PUNCT
easat-8653	71	45	1.51	1.51	NUM
easat-8653	71	46	)	)	PUNCT
easat-8653	71	47	female	female	NOUN
easat-8653	71	48	43	43	NUM
easat-8653	71	49	(	(	PUNCT
easat-8653	71	50	31.2	31.2	NUM
easat-8653	71	51	%	%	NOUN
easat-8653	71	52	)	)	PUNCT
easat-8653	71	53	95	95	NUM
easat-8653	71	54	(	(	PUNCT
easat-8653	71	55	68.8	68.8	NUM
easat-8653	71	56	%	%	NOUN
easat-8653	71	57	)	)	PUNCT
easat-8653	71	58	138	138	NUM
easat-8653	71	59	0.96	0.96	NUM
easat-8653	71	60	(	(	PUNCT
easat-8653	71	61	95	95	NUM
easat-8653	71	62	%	%	NOUN
easat-8653	71	63	ci	ci	NOUN
easat-8653	71	64	:	:	PUNCT
easat-8653	71	65	0.66	0.66	NUM
easat-8653	71	66	–	–	PUNCT
easat-8653	71	67	1.41	1.41	NUM
easat-8653	71	68	)	)	PUNCT
easat-8653	71	69	solid	solid	ADJ
easat-8653	71	70	62	62	NUM
easat-8653	71	71	(	(	PUNCT
easat-8653	71	72	33.5	33.5	NUM
easat-8653	71	73	%	%	NOUN
easat-8653	71	74	)	)	PUNCT
easat-8653	71	75	123	123	NUM
easat-8653	71	76	(	(	PUNCT
easat-8653	71	77	66.5	66.5	NUM
easat-8653	71	78	%	%	NOUN
easat-8653	71	79	)	)	PUNCT
easat-8653	71	80	185	185	NUM
easat-8653	71	81	1.34	1.34	NUM
easat-8653	71	82	(	(	PUNCT
easat-8653	71	83	95	95	NUM
easat-8653	71	84	%	%	NOUN
easat-8653	71	85	ci	ci	NOUN
easat-8653	71	86	:	:	PUNCT
easat-8653	71	87	0.80	0.80	NUM
easat-8653	71	88	–	–	PUNCT
easat-8653	71	89	2.24	2.24	NUM
easat-8653	71	90	)	)	PUNCT
easat-8653	71	91	non	non	ADJ
easat-8653	71	92	-	-	ADJ
easat-8653	71	93	solid	solid	ADJ
easat-8653	71	94	/	/	SYM
easat-8653	71	95	hematologic	hematologic	NOUN
easat-8653	71	96	13	13	NUM
easat-8653	71	97	(	(	PUNCT
easat-8653	71	98	25.0	25.0	NUM
easat-8653	71	99	%	%	NOUN
easat-8653	71	100	)	)	PUNCT
easat-8653	71	101	39	39	NUM
easat-8653	71	102	(	(	PUNCT
easat-8653	71	103	75.0	75.0	NUM
easat-8653	71	104	%	%	NOUN
easat-8653	71	105	)	)	PUNCT
easat-8653	71	106	52	52	NUM
easat-8653	71	107	0.75	0.75	NUM
easat-8653	71	108	(	(	PUNCT
easat-8653	71	109	95	95	NUM
easat-8653	71	110	%	%	NOUN
easat-8653	71	111	ci	ci	NOUN
easat-8653	71	112	:	:	PUNCT
easat-8653	71	113	0.45	0.45	NUM
easat-8653	71	114	–	–	PUNCT
easat-8653	71	115	1.25	1.25	NUM
easat-8653	71	116	)	)	PUNCT
easat-8653	71	117	with	with	ADP
easat-8653	71	118	comorbidities	comorbiditie	NOUN
easat-8653	71	119	74	74	NUM
easat-8653	71	120	(	(	PUNCT
easat-8653	71	121	41.8	41.8	NUM
easat-8653	71	122	%	%	NOUN
easat-8653	71	123	)	)	PUNCT
easat-8653	71	124	103	103	NUM
easat-8653	71	125	(	(	PUNCT
easat-8653	71	126	58.2	58.2	NUM
easat-8653	71	127	%	%	NOUN
easat-8653	71	128	)	)	PUNCT
easat-8653	71	129	177	177	NUM
easat-8653	71	130	25.08	25.08	NUM
easat-8653	71	131	(	(	PUNCT
easat-8653	71	132	95	95	NUM
easat-8653	71	133	%	%	NOUN
easat-8653	71	134	ci	ci	NOUN
easat-8653	71	135	:	:	PUNCT
easat-8653	71	136	3.56	3.56	NUM
easat-8653	71	137	–	–	PUNCT
easat-8653	71	138	176.55	176.55	NUM
easat-8653	71	139	)	)	PUNCT
easat-8653	71	140	without	without	ADP
easat-8653	71	141	comorbidities	comorbiditie	NOUN
easat-8653	71	142	1	1	NUM
easat-8653	71	143	(	(	PUNCT
easat-8653	71	144	1.7	1.7	NUM
easat-8653	71	145	%	%	NOUN
easat-8653	71	146	)	)	PUNCT
easat-8653	71	147	59	59	NUM
easat-8653	71	148	(	(	PUNCT
easat-8653	71	149	98.3	98.3	NUM
easat-8653	71	150	%	%	NOUN
easat-8653	71	151	)	)	PUNCT
easat-8653	71	152	60	60	NUM
easat-8653	71	153	0.04	0.04	NUM
easat-8653	71	154	(	(	PUNCT
easat-8653	71	155	95	95	NUM
easat-8653	71	156	%	%	NOUN
easat-8653	71	157	ci	ci	NOUN
easat-8653	71	158	:	:	PUNCT
easat-8653	71	159	0.01	0.01	NUM
easat-8653	71	160	–	–	PUNCT
easat-8653	71	161	0.28	0.28	NUM
easat-8653	71	162	)	)	PUNCT
easat-8653	71	163	total	total	NOUN
easat-8653	71	164	75	75	NUM
easat-8653	71	165	(	(	PUNCT
easat-8653	71	166	31.6	31.6	NUM
easat-8653	71	167	%	%	NOUN
easat-8653	71	168	)	)	PUNCT
easat-8653	71	169	162	162	NUM
easat-8653	71	170	(	(	PUNCT
easat-8653	71	171	68.4	68.4	NUM
easat-8653	71	172	%	%	NOUN
easat-8653	71	173	)	)	PUNCT
easat-8653	71	174	237	237	NUM
easat-8653	71	175	table	table	NOUN
easat-8653	71	176	4	4	NUM
easat-8653	71	177	.	.	PUNCT
easat-8653	71	178	relative	relative	ADJ
easat-8653	71	179	risk	risk	NOUN
easat-8653	71	180	(	(	PUNCT
easat-8653	71	181	rr	rr	NOUN
easat-8653	71	182	)	)	PUNCT
easat-8653	71	183	values	value	NOUN
easat-8653	71	184	of	of	ADP
easat-8653	71	185	independent	independent	ADJ
easat-8653	71	186	variables	variable	NOUN
easat-8653	71	187	.	.	PUNCT
easat-8653	72	1	b	b	X
easat-8653	72	2	s.e	s.e	PROPN
easat-8653	72	3	.	.	PROPN
easat-8653	72	4	wald	wald	PROPN
easat-8653	72	5	df	df	PROPN
easat-8653	72	6	exp(b	exp(b	PROPN
easat-8653	72	7	)	)	PUNCT
easat-8653	72	8	p	p	X
easat-8653	72	9	-	-	PUNCT
easat-8653	72	10	value	value	NOUN
easat-8653	72	11	constant	constant	ADJ
easat-8653	72	12	-5.325	-5.325	PROPN
easat-8653	72	13	1.355	1.355	NUM
easat-8653	72	14	15.447	15.447	NUM
easat-8653	72	15	1	1	NUM
easat-8653	72	16	0.005	0.005	NUM
easat-8653	72	17	0	0	NUM
easat-8653	72	18	gender	gender	NOUN
easat-8653	72	19	0.254	0.254	NUM
easat-8653	72	20	0.306	0.306	NUM
easat-8653	72	21	0.688	0.688	NUM
easat-8653	72	22	1	1	NUM
easat-8653	72	23	1.289	1.289	NUM
easat-8653	72	24	0.407	0.407	NUM
easat-8653	72	25	cancer	cancer	NOUN
easat-8653	72	26	type	type	NOUN
easat-8653	72	27	0.447	0.447	NUM
easat-8653	72	28	0.381	0.381	NUM
easat-8653	72	29	1.381	1.381	NUM
easat-8653	72	30	1	1	NUM
easat-8653	72	31	1.564	1.564	NUM
easat-8653	72	32	0.24	0.24	NUM
easat-8653	72	33	comorbidities	comorbiditie	NOUN
easat-8653	72	34	3.802	3.802	NUM
easat-8653	72	35	1.023	1.023	NUM
easat-8653	72	36	13.821	13.821	NUM
easat-8653	72	37	1	1	NUM
easat-8653	72	38	44.783	44.783	NUM
easat-8653	72	39	0	0	NUM
easat-8653	72	40	4	4	NUM
easat-8653	72	41	.	.	PUNCT
easat-8653	73	1	discussion	discussion	NOUN
easat-8653	73	2	this	this	DET
easat-8653	73	3	study	study	NOUN
easat-8653	73	4	examined	examine	VERB
easat-8653	73	5	mortality	mortality	NOUN
easat-8653	73	6	outcomes	outcome	NOUN
easat-8653	73	7	in	in	ADP
easat-8653	73	8	cancer	cancer	NOUN
easat-8653	73	9	patients	patient	NOUN
easat-8653	73	10	following	follow	VERB
easat-8653	73	11	covid-19	covid-19	PROPN
easat-8653	73	12	treatment	treatment	NOUN
easat-8653	73	13	and	and	CCONJ
easat-8653	73	14	found	find	VERB
easat-8653	73	15	that	that	SCONJ
easat-8653	73	16	comorbidities	comorbiditie	NOUN
easat-8653	73	17	,	,	PUNCT
easat-8653	73	18	rather	rather	ADV
easat-8653	73	19	than	than	ADP
easat-8653	73	20	cancer	cancer	NOUN
easat-8653	73	21	type	type	NOUN
easat-8653	73	22	,	,	PUNCT
easat-8653	73	23	significantly	significantly	ADV
easat-8653	73	24	influenced	influence	VERB
easat-8653	73	25	patient	patient	ADJ
easat-8653	73	26	survival	survival	NOUN
easat-8653	73	27	.	.	PUNCT
easat-8653	74	1	despite	despite	SCONJ
easat-8653	74	2	widespread	widespread	ADJ
easat-8653	74	3	assumptions	assumption	NOUN
easat-8653	74	4	that	that	SCONJ
easat-8653	74	5	hematological	hematological	ADJ
easat-8653	74	6	malignancies	malignancy	NOUN
easat-8653	74	7	would	would	AUX
easat-8653	74	8	confer	confer	VERB
easat-8653	74	9	higher	high	ADJ
easat-8653	74	10	mortality	mortality	NOUN
easat-8653	74	11	due	due	ADP
easat-8653	74	12	to	to	ADP
easat-8653	74	13	more	more	ADV
easat-8653	74	14	profound	profound	ADJ
easat-8653	74	15	immunosuppression	immunosuppression	NOUN
easat-8653	74	16	,	,	PUNCT
easat-8653	74	17	our	our	PRON
easat-8653	74	18	analysis	analysis	NOUN
easat-8653	74	19	showed	show	VERB
easat-8653	74	20	no	no	DET
easat-8653	74	21	significant	significant	ADJ
easat-8653	74	22	difference	difference	NOUN
easat-8653	74	23	in	in	ADP
easat-8653	74	24	mortality	mortality	NOUN
easat-8653	74	25	rates	rate	NOUN
easat-8653	74	26	between	between	ADP
easat-8653	74	27	solid	solid	ADJ
easat-8653	74	28	and	and	CCONJ
easat-8653	74	29	hematological	hematological	ADJ
easat-8653	74	30	cancers	cancer	NOUN
easat-8653	74	31	.	.	PUNCT
easat-8653	75	1	these	these	DET
easat-8653	75	2	findings	finding	NOUN
easat-8653	75	3	align	align	VERB
easat-8653	75	4	with	with	ADP
easat-8653	75	5	previous	previous	ADJ
easat-8653	75	6	research	research	NOUN
easat-8653	75	7	indicating	indicate	VERB
easat-8653	75	8	that	that	SCONJ
easat-8653	75	9	comorbidities	comorbiditie	NOUN
easat-8653	75	10	such	such	ADJ
easat-8653	75	11	as	as	ADP
easat-8653	75	12	cardiovascular	cardiovascular	ADJ
easat-8653	75	13	disease	disease	NOUN
easat-8653	75	14	,	,	PUNCT
easat-8653	75	15	diabetes	diabetes	NOUN
easat-8653	75	16	,	,	PUNCT
easat-8653	75	17	and	and	CCONJ
easat-8653	75	18	chronic	chronic	ADJ
easat-8653	75	19	respiratory	respiratory	ADJ
easat-8653	75	20	conditions	condition	NOUN
easat-8653	75	21	exacerbate	exacerbate	VERB
easat-8653	75	22	covid-19	covid-19	PROPN
easat-8653	75	23	outcomes	outcome	NOUN
easat-8653	75	24	[	[	X
easat-8653	75	25	7	7	NUM
easat-8653	75	26	-	-	SYM
easat-8653	75	27	9	9	NUM
easat-8653	75	28	]	]	PUNCT
easat-8653	75	29	.	.	PUNCT
easat-8653	76	1	our	our	PRON
easat-8653	76	2	results	result	NOUN
easat-8653	76	3	further	far	ADV
easat-8653	76	4	emphasize	emphasize	VERB
easat-8653	76	5	that	that	SCONJ
easat-8653	76	6	managing	manage	VERB
easat-8653	76	7	underlying	underlie	VERB
easat-8653	76	8	conditions	condition	NOUN
easat-8653	76	9	is	be	AUX
easat-8653	76	10	critical	critical	ADJ
easat-8653	76	11	in	in	ADP
easat-8653	76	12	improving	improve	VERB
easat-8653	76	13	outcomes	outcome	NOUN
easat-8653	76	14	for	for	ADP
easat-8653	76	15	cancer	cancer	NOUN
easat-8653	76	16	patients	patient	NOUN
easat-8653	76	17	,	,	PUNCT
easat-8653	76	18	regardless	regardless	ADV
easat-8653	76	19	of	of	ADP
easat-8653	76	20	tumor	tumor	NOUN
easat-8653	76	21	histology	histology	NOUN
easat-8653	76	22	.	.	PUNCT
easat-8653	77	1	the	the	DET
easat-8653	77	2	significantly	significantly	ADV
easat-8653	77	3	elevated	elevated	ADJ
easat-8653	77	4	risk	risk	NOUN
easat-8653	77	5	associated	associate	VERB
easat-8653	77	6	with	with	ADP
easat-8653	77	7	comorbidities	comorbiditie	NOUN
easat-8653	77	8	(	(	PUNCT
easat-8653	77	9	rr	rr	NOUN
easat-8653	77	10	=	=	SYM
easat-8653	77	11	25.08	25.08	NUM
easat-8653	77	12	)	)	PUNCT
easat-8653	77	13	underscores	underscore	VERB
easat-8653	77	14	the	the	DET
easat-8653	77	15	need	need	NOUN
easat-8653	77	16	for	for	ADP
easat-8653	77	17	aggressive	aggressive	ADJ
easat-8653	77	18	comorbidity	comorbidity	NOUN
easat-8653	77	19	management	management	NOUN
easat-8653	77	20	,	,	PUNCT
easat-8653	77	21	even	even	ADV
easat-8653	77	22	in	in	ADP
easat-8653	77	23	the	the	DET
easat-8653	77	24	context	context	NOUN
easat-8653	77	25	of	of	ADP
easat-8653	77	26	active	active	ADJ
easat-8653	77	27	cancer	cancer	NOUN
easat-8653	77	28	care	care	NOUN
easat-8653	77	29	.	.	PUNCT
easat-8653	78	1	the	the	DET
easat-8653	78	2	absence	absence	NOUN
easat-8653	78	3	of	of	ADP
easat-8653	78	4	statistical	statistical	ADJ
easat-8653	78	5	significance	significance	NOUN
easat-8653	78	6	between	between	ADP
easat-8653	78	7	cancer	cancer	NOUN
easat-8653	78	8	types	type	NOUN
easat-8653	78	9	suggests	suggest	VERB
easat-8653	78	10	that	that	SCONJ
easat-8653	78	11	clinical	clinical	ADJ
easat-8653	78	12	decision	decision	NOUN
easat-8653	78	13	-	-	PUNCT
easat-8653	78	14	making	making	NOUN
easat-8653	78	15	should	should	AUX
easat-8653	78	16	focus	focus	VERB
easat-8653	78	17	more	more	ADV
easat-8653	78	18	on	on	ADP
easat-8653	78	19	patientspecific	patientspecific	ADJ
easat-8653	78	20	risk	risk	NOUN
easat-8653	78	21	factors	factor	NOUN
easat-8653	78	22	rather	rather	ADV
easat-8653	78	23	than	than	ADP
easat-8653	78	24	tumor	tumor	NOUN
easat-8653	78	25	classification	classification	NOUN
easat-8653	78	26	alone	alone	ADV
easat-8653	78	27	.	.	PUNCT
easat-8653	79	1	limitations	limitation	NOUN
easat-8653	79	2	of	of	ADP
easat-8653	79	3	the	the	DET
easat-8653	79	4	study	study	NOUN
easat-8653	79	5	include	include	VERB
easat-8653	79	6	its	its	PRON
easat-8653	79	7	retrospective	retrospective	ADJ
easat-8653	79	8	design	design	NOUN
easat-8653	79	9	,	,	PUNCT
easat-8653	79	10	which	which	PRON
easat-8653	79	11	may	may	AUX
easat-8653	79	12	introduce	introduce	VERB
easat-8653	79	13	bias	bias	NOUN
easat-8653	79	14	due	due	ADP
easat-8653	79	15	to	to	ADP
easat-8653	79	16	incomplete	incomplete	ADJ
easat-8653	79	17	data	datum	NOUN
easat-8653	79	18	documentation	documentation	NOUN
easat-8653	79	19	.	.	PUNCT
easat-8653	80	1	in	in	ADP
easat-8653	80	2	addition	addition	NOUN
easat-8653	80	3	,	,	PUNCT
easat-8653	80	4	treatment	treatment	NOUN
easat-8653	80	5	modalities	modality	NOUN
easat-8653	80	6	and	and	CCONJ
easat-8653	80	7	timing	timing	NOUN
easat-8653	80	8	for	for	ADP
easat-8653	80	9	both	both	DET
easat-8653	80	10	cancer	cancer	NOUN
easat-8653	80	11	and	and	CCONJ
easat-8653	80	12	covid-19	covid-19	PROPN
easat-8653	80	13	were	be	AUX
easat-8653	80	14	not	not	PART
easat-8653	80	15	analyzed	analyze	VERB
easat-8653	80	16	,	,	PUNCT
easat-8653	80	17	which	which	PRON
easat-8653	80	18	could	could	AUX
easat-8653	80	19	influence	influence	VERB
easat-8653	80	20	mortality	mortality	NOUN
easat-8653	80	21	.	.	PUNCT
easat-8653	81	1	nevertheless	nevertheless	ADV
easat-8653	81	2	,	,	PUNCT
easat-8653	81	3	the	the	DET
easat-8653	81	4	findings	finding	NOUN
easat-8653	81	5	provide	provide	VERB
easat-8653	81	6	valuable	valuable	ADJ
easat-8653	81	7	insight	insight	NOUN
easat-8653	81	8	into	into	ADP
easat-8653	81	9	prioritizing	prioritize	VERB
easat-8653	81	10	supportive	supportive	ADJ
easat-8653	81	11	care	care	NOUN
easat-8653	81	12	and	and	CCONJ
easat-8653	81	13	comorbidity	comorbidity	NOUN
easat-8653	81	14	screening	screen	VERB
easat-8653	81	15	in	in	ADP
easat-8653	81	16	oncologic	oncologic	ADJ
easat-8653	81	17	patients	patient	NOUN
easat-8653	81	18	during	during	ADP
easat-8653	81	19	infectious	infectious	ADJ
easat-8653	81	20	disease	disease	NOUN
easat-8653	81	21	outbreaks	outbreak	NOUN
easat-8653	81	22	such	such	ADJ
easat-8653	81	23	as	as	ADP
easat-8653	81	24	covid-19	covid-19	PROPN
easat-8653	81	25	.	.	PROPN
easat-8653	81	26	5	5	NUM
easat-8653	81	27	.	.	PUNCT
easat-8653	81	28	conclusion	conclusion	NOUN
easat-8653	81	29	comorbidities	comorbiditie	NOUN
easat-8653	81	30	are	be	AUX
easat-8653	81	31	the	the	DET
easat-8653	81	32	primary	primary	ADJ
easat-8653	81	33	determinant	determinant	NOUN
easat-8653	81	34	of	of	ADP
easat-8653	81	35	mortality	mortality	NOUN
easat-8653	81	36	among	among	ADP
easat-8653	81	37	cancer	cancer	NOUN
easat-8653	81	38	patients	patient	NOUN
easat-8653	81	39	following	follow	VERB
easat-8653	81	40	covid19	covid19	NOUN
easat-8653	81	41	treatment	treatment	NOUN
easat-8653	81	42	,	,	PUNCT
easat-8653	81	43	regardless	regardless	ADV
easat-8653	81	44	of	of	ADP
easat-8653	81	45	whether	whether	SCONJ
easat-8653	81	46	the	the	DET
easat-8653	81	47	malignancy	malignancy	NOUN
easat-8653	81	48	is	be	AUX
easat-8653	81	49	of	of	ADP
easat-8653	81	50	solid	solid	ADJ
easat-8653	81	51	or	or	CCONJ
easat-8653	81	52	hematological	hematological	ADJ
easat-8653	81	53	origin	origin	NOUN
easat-8653	81	54	.	.	PUNCT
easat-8653	82	1	these	these	DET
easat-8653	82	2	findings	finding	NOUN
easat-8653	82	3	highlight	highlight	VERB
easat-8653	82	4	the	the	DET
easat-8653	82	5	importance	importance	NOUN
easat-8653	82	6	of	of	ADP
easat-8653	82	7	aggressive	aggressive	ADJ
easat-8653	82	8	identification	identification	NOUN
easat-8653	82	9	and	and	CCONJ
easat-8653	82	10	management	management	NOUN
easat-8653	82	11	of	of	ADP
easat-8653	82	12	comorbid	comorbid	NOUN
easat-8653	82	13	conditions	condition	NOUN
easat-8653	82	14	in	in	ADP
easat-8653	82	15	cancer	cancer	NOUN
easat-8653	82	16	patients	patient	NOUN
easat-8653	82	17	to	to	PART
easat-8653	82	18	reduce	reduce	VERB
easat-8653	82	19	the	the	DET
easat-8653	82	20	risk	risk	NOUN
easat-8653	82	21	of	of	ADP
easat-8653	82	22	fatal	fatal	ADJ
easat-8653	82	23	outcomes	outcome	NOUN
easat-8653	82	24	in	in	ADP
easat-8653	82	25	the	the	DET
easat-8653	82	26	context	context	NOUN
easat-8653	82	27	of	of	ADP
easat-8653	82	28	infectious	infectious	ADJ
easat-8653	82	29	disease	disease	NOUN
easat-8653	82	30	pandemics	pandemic	NOUN
easat-8653	82	31	.	.	PUNCT
easat-8653	83	1	future	future	ADJ
easat-8653	83	2	research	research	NOUN
easat-8653	83	3	should	should	AUX
easat-8653	83	4	explore	explore	VERB
easat-8653	83	5	prospective	prospective	ADJ
easat-8653	83	6	multicenter	multicenter	NOUN
easat-8653	83	7	data	datum	NOUN
easat-8653	83	8	and	and	CCONJ
easat-8653	83	9	incorporate	incorporate	VERB
easat-8653	83	10	treatment	treatment	NOUN
easat-8653	83	11	variables	variable	NOUN
easat-8653	83	12	to	to	PART
easat-8653	83	13	further	far	ADV
easat-8653	83	14	refine	refine	VERB
easat-8653	83	15	mortality	mortality	NOUN
easat-8653	83	16	risk	risk	NOUN
easat-8653	83	17	assessments	assessment	NOUN
easat-8653	83	18	.	.	PUNCT
easat-8653	84	1	transparency	transparency	NOUN
easat-8653	84	2	:	:	PUNCT
easat-8653	84	3	the	the	DET
easat-8653	84	4	authors	author	NOUN
easat-8653	84	5	confirm	confirm	VERB
easat-8653	84	6	that	that	SCONJ
easat-8653	84	7	the	the	DET
easat-8653	84	8	manuscript	manuscript	NOUN
easat-8653	84	9	is	be	AUX
easat-8653	84	10	an	an	DET
easat-8653	84	11	honest	honest	ADJ
easat-8653	84	12	,	,	PUNCT
easat-8653	84	13	accurate	accurate	ADJ
easat-8653	84	14	,	,	PUNCT
easat-8653	84	15	and	and	CCONJ
easat-8653	84	16	transparent	transparent	ADJ
easat-8653	84	17	account	account	NOUN
easat-8653	84	18	of	of	ADP
easat-8653	84	19	the	the	DET
easat-8653	84	20	study	study	NOUN
easat-8653	84	21	;	;	PUNCT
easat-8653	84	22	that	that	SCONJ
easat-8653	84	23	no	no	DET
easat-8653	84	24	vital	vital	ADJ
easat-8653	84	25	features	feature	NOUN
easat-8653	84	26	of	of	ADP
easat-8653	84	27	the	the	DET
easat-8653	84	28	study	study	NOUN
easat-8653	84	29	have	have	AUX
easat-8653	84	30	been	be	AUX
easat-8653	84	31	omitted	omit	VERB
easat-8653	84	32	;	;	PUNCT
easat-8653	84	33	and	and	CCONJ
easat-8653	84	34	that	that	SCONJ
easat-8653	84	35	any	any	DET
easat-8653	84	36	discrepancies	discrepancy	NOUN
easat-8653	84	37	from	from	ADP
easat-8653	84	38	the	the	DET
easat-8653	84	39	study	study	NOUN
easat-8653	84	40	as	as	SCONJ
easat-8653	84	41	planned	plan	VERB
easat-8653	84	42	have	have	AUX
easat-8653	84	43	been	be	AUX
easat-8653	84	44	explained	explain	VERB
easat-8653	84	45	.	.	PUNCT
easat-8653	85	1	this	this	DET
easat-8653	85	2	study	study	NOUN
easat-8653	85	3	followed	follow	VERB
easat-8653	85	4	all	all	DET
easat-8653	85	5	ethical	ethical	ADJ
easat-8653	85	6	practices	practice	NOUN
easat-8653	85	7	during	during	ADP
easat-8653	85	8	writing	writing	NOUN
easat-8653	85	9	.	.	PUNCT
easat-8653	86	1	535	535	NUM
easat-8653	86	2	edelweiss	edelweiss	PROPN
easat-8653	86	3	applied	apply	VERB
easat-8653	86	4	science	science	NOUN
easat-8653	86	5	and	and	CCONJ
easat-8653	86	6	technology	technology	NOUN
easat-8653	86	7	issn	issn	PROPN
easat-8653	86	8	:	:	PUNCT
easat-8653	86	9	2576	2576	NUM
easat-8653	86	10	-	-	SYM
easat-8653	86	11	8484	8484	NUM
easat-8653	86	12	vol	vol	NOUN
easat-8653	86	13	.	.	PROPN
easat-8653	87	1	9	9	NUM
easat-8653	87	2	,	,	PUNCT
easat-8653	87	3	no	no	INTJ
easat-8653	87	4	.	.	NOUN
easat-8653	87	5	7	7	NUM
easat-8653	87	6	:	:	PUNCT
easat-8653	87	7	529	529	NUM
easat-8653	87	8	-	-	SYM
easat-8653	87	9	535	535	NUM
easat-8653	87	10	,	,	PUNCT
easat-8653	87	11	2025	2025	NUM
easat-8653	87	12	doi	doi	NOUN
easat-8653	87	13	:	:	PUNCT
easat-8653	87	14	10.55214/25768484.v9i7.8653	10.55214/25768484.v9i7.8653	PROPN
easat-8653	87	15	©	©	PROPN
easat-8653	87	16	2025	2025	NUM
easat-8653	87	17	by	by	ADP
easat-8653	87	18	the	the	DET
easat-8653	87	19	authors	author	NOUN
easat-8653	87	20	;	;	PUNCT
easat-8653	87	21	licensee	licensee	PROPN
easat-8653	87	22	learning	learn	VERB
easat-8653	87	23	gate	gate	NOUN
easat-8653	87	24	copyright	copyright	NOUN
easat-8653	87	25	:	:	PUNCT
easat-8653	87	26	©	©	PROPN
easat-8653	87	27	2025	2025	NUM
easat-8653	87	28	by	by	ADP
easat-8653	87	29	the	the	DET
easat-8653	87	30	authors	author	NOUN
easat-8653	87	31	.	.	PUNCT
easat-8653	88	1	this	this	DET
easat-8653	88	2	open	open	ADJ
easat-8653	88	3	-	-	PUNCT
easat-8653	88	4	access	access	NOUN
easat-8653	88	5	article	article	NOUN
easat-8653	88	6	is	be	AUX
easat-8653	88	7	distributed	distribute	VERB
easat-8653	88	8	under	under	ADP
easat-8653	88	9	the	the	DET
easat-8653	88	10	terms	term	NOUN
easat-8653	88	11	and	and	CCONJ
easat-8653	88	12	conditions	condition	NOUN
easat-8653	88	13	of	of	ADP
easat-8653	88	14	the	the	DET
easat-8653	88	15	creative	creative	ADJ
easat-8653	88	16	commons	common	NOUN
easat-8653	88	17	attribution	attribution	NOUN
easat-8653	88	18	(	(	PUNCT
easat-8653	88	19	cc	cc	NOUN
easat-8653	88	20	by	by	ADP
easat-8653	88	21	)	)	PUNCT
easat-8653	88	22	license	license	NOUN
easat-8653	88	23	(	(	PUNCT
easat-8653	88	24	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
easat-8653	88	25	)	)	PUNCT
easat-8653	88	26	.	.	PUNCT
easat-8653	89	1	references	reference	NOUN
easat-8653	89	2	[	[	X
easat-8653	89	3	1	1	NUM
easat-8653	89	4	]	]	PUNCT
easat-8653	89	5	z.	z.	PROPN
easat-8653	89	6	zheng	zheng	PROPN
easat-8653	89	7	et	et	PROPN
easat-8653	89	8	al	al	PROPN
easat-8653	89	9	.	.	PROPN
easat-8653	89	10	,	,	PUNCT
easat-8653	89	11	"	"	PUNCT
easat-8653	89	12	risk	risk	NOUN
easat-8653	89	13	factors	factor	NOUN
easat-8653	89	14	of	of	ADP
easat-8653	89	15	critical	critical	ADJ
easat-8653	89	16	&	&	CCONJ
easat-8653	89	17	amp	amp	NOUN
easat-8653	89	18	;	;	PUNCT
easat-8653	89	19	mortal	mortal	ADJ
easat-8653	89	20	covid-19	covid-19	PROPN
easat-8653	89	21	cases	case	NOUN
easat-8653	89	22	:	:	PUNCT
easat-8653	89	23	a	a	DET
easat-8653	89	24	systematic	systematic	ADJ
easat-8653	89	25	literature	literature	NOUN
easat-8653	89	26	review	review	NOUN
easat-8653	89	27	and	and	CCONJ
easat-8653	89	28	metaanalysis	metaanalysis	NOUN
easat-8653	89	29	,	,	PUNCT
easat-8653	89	30	"	"	PUNCT
easat-8653	89	31	journal	journal	NOUN
easat-8653	89	32	of	of	ADP
easat-8653	89	33	infection	infection	NOUN
easat-8653	89	34	,	,	PUNCT
easat-8653	89	35	vol	vol	NOUN
easat-8653	89	36	.	.	PROPN
easat-8653	89	37	81	81	NUM
easat-8653	89	38	,	,	PUNCT
easat-8653	89	39	no	no	INTJ
easat-8653	89	40	.	.	NOUN
easat-8653	89	41	2	2	NUM
easat-8653	89	42	,	,	PUNCT
easat-8653	89	43	pp	pp	PROPN
easat-8653	89	44	.	.	PUNCT
easat-8653	90	1	e16	e16	PROPN
easat-8653	90	2	-	-	PUNCT
easat-8653	90	3	e25	e25	PROPN
easat-8653	90	4	,	,	PUNCT
easat-8653	90	5	2020	2020	NUM
easat-8653	90	6	.	.	PUNCT
easat-8653	91	1	https://doi.org/10.1016/j.jinf.2020.04.021	https://doi.org/10.1016/j.jinf.2020.04.021	NOUN
easat-8653	92	1	[	[	X
easat-8653	92	2	2	2	NUM
easat-8653	92	3	]	]	PUNCT
easat-8653	92	4	k.	k.	PROPN
easat-8653	92	5	kishor	kishor	PROPN
easat-8653	92	6	et	et	PROPN
easat-8653	92	7	al	al	PROPN
easat-8653	92	8	.	.	PROPN
easat-8653	92	9	,	,	PUNCT
easat-8653	92	10	"	"	PUNCT
easat-8653	92	11	brain	brain	NOUN
easat-8653	92	12	tumor	tumor	NOUN
easat-8653	92	13	management	management	NOUN
easat-8653	92	14	amidst	amidst	ADP
easat-8653	92	15	covid-19	covid-19	PROPN
easat-8653	92	16	pandemic	pandemic	NOUN
easat-8653	92	17	,	,	PUNCT
easat-8653	92	18	"	"	PUNCT
easat-8653	92	19	asian	asian	PROPN
easat-8653	92	20	pacific	pacific	PROPN
easat-8653	92	21	journal	journal	PROPN
easat-8653	92	22	of	of	ADP
easat-8653	92	23	cancer	cancer	NOUN
easat-8653	92	24	care	care	NOUN
easat-8653	92	25	,	,	PUNCT
easat-8653	92	26	vol	vol	NOUN
easat-8653	92	27	.	.	PROPN
easat-8653	92	28	5	5	NUM
easat-8653	92	29	,	,	PUNCT
easat-8653	92	30	no	no	INTJ
easat-8653	92	31	.	.	PUNCT
easat-8653	93	1	s1	s1	NOUN
easat-8653	93	2	,	,	PUNCT
easat-8653	93	3	pp	pp	ADJ
easat-8653	93	4	.	.	PUNCT
easat-8653	94	1	235	235	NUM
easat-8653	94	2	-	-	SYM
easat-8653	94	3	238	238	NUM
easat-8653	94	4	,	,	PUNCT
easat-8653	94	5	2020	2020	NUM
easat-8653	94	6	.	.	PUNCT
easat-8653	95	1	[	[	X
easat-8653	95	2	3	3	X
easat-8653	95	3	]	]	X
easat-8653	95	4	g.	g.	PROPN
easat-8653	95	5	m.	m.	PROPN
easat-8653	95	6	elgohary	elgohary	ADP
easat-8653	95	7	et	et	PROPN
easat-8653	95	8	al	al	PROPN
easat-8653	95	9	.	.	PROPN
easat-8653	95	10	,	,	PUNCT
easat-8653	95	11	"	"	PUNCT
easat-8653	95	12	the	the	DET
easat-8653	95	13	risk	risk	NOUN
easat-8653	95	14	and	and	CCONJ
easat-8653	95	15	prognosis	prognosis	NOUN
easat-8653	95	16	of	of	ADP
easat-8653	95	17	covid-19	covid-19	PROPN
easat-8653	95	18	infection	infection	NOUN
easat-8653	95	19	in	in	ADP
easat-8653	95	20	cancer	cancer	NOUN
easat-8653	95	21	patients	patient	NOUN
easat-8653	95	22	:	:	PUNCT
easat-8653	95	23	a	a	DET
easat-8653	95	24	systematic	systematic	ADJ
easat-8653	95	25	review	review	NOUN
easat-8653	95	26	and	and	CCONJ
easat-8653	95	27	meta	meta	ADJ
easat-8653	95	28	-	-	PUNCT
easat-8653	95	29	analysis	analysis	NOUN
easat-8653	95	30	,	,	PUNCT
easat-8653	95	31	"	"	PUNCT
easat-8653	95	32	hematology	hematology	NOUN
easat-8653	95	33	/	/	SYM
easat-8653	95	34	oncology	oncology	NOUN
easat-8653	95	35	and	and	CCONJ
easat-8653	95	36	stem	stem	NOUN
easat-8653	95	37	cell	cell	NOUN
easat-8653	95	38	therapy	therapy	NOUN
easat-8653	95	39	,	,	PUNCT
easat-8653	95	40	vol	vol	NOUN
easat-8653	95	41	.	.	PROPN
easat-8653	95	42	15	15	NUM
easat-8653	95	43	,	,	PUNCT
easat-8653	95	44	no	no	INTJ
easat-8653	95	45	.	.	NOUN
easat-8653	95	46	2	2	NUM
easat-8653	95	47	,	,	PUNCT
easat-8653	95	48	pp	pp	ADJ
easat-8653	95	49	.	.	PUNCT
easat-8653	96	1	45	45	NUM
easat-8653	96	2	-	-	SYM
easat-8653	96	3	53	53	NUM
easat-8653	96	4	,	,	PUNCT
easat-8653	96	5	2022	2022	NUM
easat-8653	96	6	.	.	PUNCT
easat-8653	97	1	https://doi.org/10.1016/j.hemonc.2020.07.005	https://doi.org/10.1016/j.hemonc.2020.07.005	VERB
easat-8653	97	2	[	[	X
easat-8653	97	3	4	4	NUM
easat-8653	97	4	]	]	X
easat-8653	97	5	n.	n.	PROPN
easat-8653	97	6	r.	r.	PROPN
easat-8653	97	7	fillmore	fillmore	PROPN
easat-8653	97	8	,	,	PUNCT
easat-8653	97	9	j.	j.	PROPN
easat-8653	97	10	la	la	PROPN
easat-8653	97	11	,	,	PUNCT
easat-8653	97	12	r.	r.	PROPN
easat-8653	97	13	e.	e.	PROPN
easat-8653	97	14	szalat	szalat	PROPN
easat-8653	97	15	,	,	PUNCT
easat-8653	97	16	d.	d.	PROPN
easat-8653	97	17	p.	p.	PROPN
easat-8653	97	18	tuck	tuck	PROPN
easat-8653	97	19	,	,	PUNCT
easat-8653	97	20	v.	v.	CCONJ
easat-8653	97	21	nguyen	nguyen	NOUN
easat-8653	97	22	,	,	PUNCT
easat-8653	97	23	and	and	CCONJ
easat-8653	97	24	c.	c.	PROPN
easat-8653	97	25	yildirim	yildirim	PROPN
easat-8653	97	26	,	,	PUNCT
easat-8653	97	27	"	"	PUNCT
easat-8653	97	28	prevalence	prevalence	NOUN
easat-8653	97	29	and	and	CCONJ
easat-8653	97	30	outcome	outcome	NOUN
easat-8653	97	31	of	of	ADP
easat-8653	97	32	covid-19	covid-19	PROPN
easat-8653	97	33	infection	infection	NOUN
easat-8653	97	34	in	in	ADP
easat-8653	97	35	cancer	cancer	NOUN
easat-8653	97	36	patients	patient	NOUN
easat-8653	97	37	:	:	PUNCT
easat-8653	97	38	a	a	DET
easat-8653	97	39	national	national	ADJ
easat-8653	97	40	veterans	veterans	PROPN
easat-8653	97	41	affairs	affair	NOUN
easat-8653	97	42	study	study	NOUN
easat-8653	97	43	,	,	PUNCT
easat-8653	97	44	"	"	PUNCT
easat-8653	97	45	journal	journal	NOUN
easat-8653	97	46	of	of	ADP
easat-8653	97	47	the	the	DET
easat-8653	97	48	national	national	PROPN
easat-8653	97	49	cancer	cancer	PROPN
easat-8653	97	50	institute	institute	PROPN
easat-8653	97	51	,	,	PUNCT
easat-8653	97	52	vol	vol	NOUN
easat-8653	97	53	.	.	PROPN
easat-8653	97	54	113	113	NUM
easat-8653	97	55	,	,	PUNCT
easat-8653	97	56	no	no	INTJ
easat-8653	97	57	.	.	NOUN
easat-8653	97	58	6	6	NUM
easat-8653	97	59	,	,	PUNCT
easat-8653	97	60	pp	pp	ADJ
easat-8653	97	61	.	.	PUNCT
easat-8653	98	1	691–698	691–698	NUM
easat-8653	98	2	,	,	PUNCT
easat-8653	98	3	2021	2021	NUM
easat-8653	98	4	.	.	PUNCT
easat-8653	99	1	[	[	X
easat-8653	99	2	5	5	X
easat-8653	99	3	]	]	PUNCT
easat-8653	99	4	h.	h.	PROPN
easat-8653	99	5	zhang	zhang	PROPN
easat-8653	99	6	,	,	PUNCT
easat-8653	99	7	c.	c.	PROPN
easat-8653	99	8	xie	xie	PROPN
easat-8653	99	9	,	,	PUNCT
easat-8653	99	10	and	and	CCONJ
easat-8653	99	11	y.	y.	PROPN
easat-8653	99	12	huang	huang	PROPN
easat-8653	99	13	,	,	PUNCT
easat-8653	99	14	"	"	PUNCT
easat-8653	99	15	treatment	treatment	NOUN
easat-8653	99	16	and	and	CCONJ
easat-8653	99	17	outcome	outcome	NOUN
easat-8653	99	18	of	of	ADP
easat-8653	99	19	a	a	DET
easat-8653	99	20	patient	patient	NOUN
easat-8653	99	21	with	with	ADP
easat-8653	99	22	lung	lung	NOUN
easat-8653	99	23	cancer	cancer	NOUN
easat-8653	99	24	infected	infect	VERB
easat-8653	99	25	with	with	ADP
easat-8653	99	26	severe	severe	ADJ
easat-8653	99	27	acute	acute	ADJ
easat-8653	99	28	respiratory	respiratory	ADJ
easat-8653	99	29	syndrome	syndrome	NOUN
easat-8653	99	30	coronavirus-2	coronavirus-2	NUM
easat-8653	99	31	,	,	PUNCT
easat-8653	99	32	"	"	PUNCT
easat-8653	99	33	journal	journal	NOUN
easat-8653	99	34	of	of	ADP
easat-8653	99	35	thoracic	thoracic	NOUN
easat-8653	99	36	oncology	oncology	NOUN
easat-8653	99	37	,	,	PUNCT
easat-8653	99	38	vol	vol	NOUN
easat-8653	99	39	.	.	PROPN
easat-8653	99	40	15	15	NUM
easat-8653	99	41	,	,	PUNCT
easat-8653	99	42	no	no	INTJ
easat-8653	99	43	.	.	NOUN
easat-8653	99	44	5	5	NUM
easat-8653	99	45	,	,	PUNCT
easat-8653	99	46	pp	pp	PROPN
easat-8653	99	47	.	.	PUNCT
easat-8653	99	48	e63	e63	NOUN
easat-8653	99	49	-	-	PUNCT
easat-8653	99	50	e64	e64	PROPN
easat-8653	99	51	,	,	PUNCT
easat-8653	99	52	2020	2020	NUM
easat-8653	99	53	.	.	PUNCT
easat-8653	100	1	[	[	X
easat-8653	100	2	6	6	NUM
easat-8653	100	3	]	]	PUNCT
easat-8653	100	4	l.	l.	PROPN
easat-8653	100	5	y.	y.	PROPN
easat-8653	100	6	lee	lee	PROPN
easat-8653	100	7	et	et	PROPN
easat-8653	100	8	al	al	PROPN
easat-8653	100	9	.	.	PROPN
easat-8653	100	10	,	,	PUNCT
easat-8653	100	11	"	"	PUNCT
easat-8653	100	12	covid-19	covid-19	PROPN
easat-8653	100	13	prevalence	prevalence	NOUN
easat-8653	100	14	and	and	CCONJ
easat-8653	100	15	mortality	mortality	NOUN
easat-8653	100	16	in	in	ADP
easat-8653	100	17	patients	patient	NOUN
easat-8653	100	18	with	with	ADP
easat-8653	100	19	cancer	cancer	NOUN
easat-8653	100	20	and	and	CCONJ
easat-8653	100	21	the	the	DET
easat-8653	100	22	effect	effect	NOUN
easat-8653	100	23	of	of	ADP
easat-8653	100	24	primary	primary	ADJ
easat-8653	100	25	tumour	tumour	NOUN
easat-8653	100	26	subtype	subtype	NOUN
easat-8653	100	27	and	and	CCONJ
easat-8653	100	28	patient	patient	ADJ
easat-8653	100	29	demographics	demographic	NOUN
easat-8653	100	30	:	:	PUNCT
easat-8653	100	31	a	a	DET
easat-8653	100	32	prospective	prospective	ADJ
easat-8653	100	33	cohort	cohort	NOUN
easat-8653	100	34	study	study	NOUN
easat-8653	100	35	,	,	PUNCT
easat-8653	100	36	"	"	PUNCT
easat-8653	100	37	the	the	DET
easat-8653	100	38	lancet	lancet	PROPN
easat-8653	100	39	oncology	oncology	NOUN
easat-8653	100	40	,	,	PUNCT
easat-8653	100	41	vol	vol	NOUN
easat-8653	100	42	.	.	PROPN
easat-8653	100	43	21	21	NUM
easat-8653	100	44	,	,	PUNCT
easat-8653	100	45	no	no	INTJ
easat-8653	100	46	.	.	NOUN
easat-8653	100	47	10	10	NUM
easat-8653	100	48	,	,	PUNCT
easat-8653	100	49	pp	pp	ADJ
easat-8653	100	50	.	.	PUNCT
easat-8653	100	51	1309	1309	NUM
easat-8653	100	52	-	-	SYM
easat-8653	100	53	1316	1316	NUM
easat-8653	100	54	,	,	PUNCT
easat-8653	100	55	2020	2020	NUM
easat-8653	100	56	.	.	PUNCT
easat-8653	101	1	[	[	X
easat-8653	101	2	7	7	X
easat-8653	101	3	]	]	X
easat-8653	101	4	n.	n.	PROPN
easat-8653	101	5	chen	chen	PROPN
easat-8653	101	6	et	et	PROPN
easat-8653	101	7	al	al	PROPN
easat-8653	101	8	.	.	PROPN
easat-8653	101	9	,	,	PUNCT
easat-8653	101	10	"	"	PUNCT
easat-8653	101	11	epidemiological	epidemiological	ADJ
easat-8653	101	12	and	and	CCONJ
easat-8653	101	13	clinical	clinical	ADJ
easat-8653	101	14	characteristics	characteristic	NOUN
easat-8653	101	15	of	of	ADP
easat-8653	101	16	99	99	NUM
easat-8653	101	17	cases	case	NOUN
easat-8653	101	18	of	of	ADP
easat-8653	101	19	2019	2019	NUM
easat-8653	101	20	novel	novel	ADJ
easat-8653	101	21	coronavirus	coronavirus	NOUN
easat-8653	101	22	pneumonia	pneumonia	NOUN
easat-8653	101	23	in	in	ADP
easat-8653	101	24	wuhan	wuhan	PROPN
easat-8653	101	25	,	,	PUNCT
easat-8653	101	26	china	china	PROPN
easat-8653	101	27	:	:	PUNCT
easat-8653	101	28	a	a	DET
easat-8653	101	29	descriptive	descriptive	ADJ
easat-8653	101	30	study	study	NOUN
easat-8653	101	31	,	,	PUNCT
easat-8653	101	32	"	"	PUNCT
easat-8653	101	33	the	the	DET
easat-8653	101	34	lancet	lancet	NOUN
easat-8653	101	35	,	,	PUNCT
easat-8653	101	36	vol	vol	NOUN
easat-8653	101	37	.	.	PROPN
easat-8653	102	1	395	395	NUM
easat-8653	102	2	,	,	PUNCT
easat-8653	102	3	no	no	NOUN
easat-8653	102	4	.	.	NOUN
easat-8653	102	5	10223	10223	NUM
easat-8653	102	6	,	,	PUNCT
easat-8653	102	7	pp	pp	ADJ
easat-8653	102	8	.	.	PUNCT
easat-8653	103	1	507	507	NUM
easat-8653	103	2	-	-	SYM
easat-8653	103	3	513	513	NUM
easat-8653	103	4	,	,	PUNCT
easat-8653	103	5	2020	2020	NUM
easat-8653	103	6	.	.	PUNCT
easat-8653	104	1	https://doi.org/10.1016/s0140-6736(20)30211-7	https://doi.org/10.1016/s0140-6736(20)30211-7	PROPN
easat-8653	105	1	[	[	X
easat-8653	105	2	8	8	NUM
easat-8653	105	3	]	]	PUNCT
easat-8653	106	1	x.	x.	NOUN
easat-8653	106	2	yang	yang	PROPN
easat-8653	106	3	et	et	PROPN
easat-8653	106	4	al	al	PROPN
easat-8653	106	5	.	.	PROPN
easat-8653	106	6	,	,	PUNCT
easat-8653	106	7	"	"	PUNCT
easat-8653	106	8	clinical	clinical	ADJ
easat-8653	106	9	course	course	NOUN
easat-8653	106	10	and	and	CCONJ
easat-8653	106	11	outcomes	outcome	NOUN
easat-8653	106	12	of	of	ADP
easat-8653	106	13	critically	critically	ADV
easat-8653	106	14	ill	ill	ADJ
easat-8653	106	15	patients	patient	NOUN
easat-8653	106	16	with	with	ADP
easat-8653	106	17	sars	sar	NOUN
easat-8653	106	18	-	-	PUNCT
easat-8653	106	19	cov-2	cov-2	NOUN
easat-8653	106	20	pneumonia	pneumonia	NOUN
easat-8653	106	21	in	in	ADP
easat-8653	106	22	wuhan	wuhan	PROPN
easat-8653	106	23	,	,	PUNCT
easat-8653	106	24	china	china	PROPN
easat-8653	106	25	:	:	PUNCT
easat-8653	106	26	a	a	DET
easat-8653	106	27	single	single	ADJ
easat-8653	106	28	-	-	PUNCT
easat-8653	106	29	centered	center	VERB
easat-8653	106	30	,	,	PUNCT
easat-8653	106	31	retrospective	retrospective	ADJ
easat-8653	106	32	,	,	PUNCT
easat-8653	106	33	observational	observational	ADJ
easat-8653	106	34	study	study	NOUN
easat-8653	106	35	,	,	PUNCT
easat-8653	106	36	"	"	PUNCT
easat-8653	106	37	the	the	DET
easat-8653	106	38	lancet	lancet	ADJ
easat-8653	106	39	respiratory	respiratory	ADJ
easat-8653	106	40	medicine	medicine	NOUN
easat-8653	106	41	,	,	PUNCT
easat-8653	106	42	vol	vol	NOUN
easat-8653	106	43	.	.	PROPN
easat-8653	106	44	8	8	NUM
easat-8653	106	45	,	,	PUNCT
easat-8653	106	46	no	no	INTJ
easat-8653	106	47	.	.	NOUN
easat-8653	106	48	5	5	NUM
easat-8653	106	49	,	,	PUNCT
easat-8653	106	50	pp	pp	ADJ
easat-8653	106	51	.	.	PUNCT
easat-8653	107	1	475	475	NUM
easat-8653	107	2	-	-	SYM
easat-8653	107	3	481	481	NUM
easat-8653	107	4	,	,	PUNCT
easat-8653	107	5	2020	2020	NUM
easat-8653	107	6	.	.	PUNCT
easat-8653	108	1	[	[	X
easat-8653	108	2	9	9	NUM
easat-8653	108	3	]	]	PUNCT
easat-8653	108	4	s.	s.	PROPN
easat-8653	108	5	richardson	richardson	PROPN
easat-8653	108	6	,	,	PUNCT
easat-8653	108	7	j.	j.	PROPN
easat-8653	108	8	s.	s.	PROPN
easat-8653	108	9	hirsch	hirsch	PROPN
easat-8653	108	10	,	,	PUNCT
easat-8653	108	11	m.	m.	NOUN
easat-8653	108	12	narasimhan	narasimhan	PROPN
easat-8653	108	13	,	,	PUNCT
easat-8653	108	14	j.	j.	PROPN
easat-8653	108	15	m.	m.	PROPN
easat-8653	108	16	crawford	crawford	PROPN
easat-8653	108	17	,	,	PUNCT
easat-8653	108	18	t.	t.	PROPN
easat-8653	108	19	mcginn	mcginn	PROPN
easat-8653	108	20	,	,	PUNCT
easat-8653	108	21	and	and	CCONJ
easat-8653	108	22	k.	k.	PROPN
easat-8653	108	23	w.	w.	PROPN
easat-8653	108	24	davidson	davidson	PROPN
easat-8653	108	25	,	,	PUNCT
easat-8653	108	26	"	"	PUNCT
easat-8653	108	27	presenting	present	VERB
easat-8653	108	28	characteristics	characteristic	NOUN
easat-8653	108	29	,	,	PUNCT
easat-8653	108	30	comorbidities	comorbiditie	NOUN
easat-8653	108	31	,	,	PUNCT
easat-8653	108	32	and	and	CCONJ
easat-8653	108	33	outcomes	outcome	NOUN
easat-8653	108	34	among	among	ADP
easat-8653	108	35	5700	5700	NUM
easat-8653	108	36	patients	patient	NOUN
easat-8653	108	37	hospitalized	hospitalize	VERB
easat-8653	108	38	with	with	ADP
easat-8653	108	39	covid-19	covid-19	PROPN
easat-8653	108	40	in	in	ADP
easat-8653	108	41	the	the	DET
easat-8653	108	42	new	new	PROPN
easat-8653	108	43	york	york	PROPN
easat-8653	108	44	city	city	PROPN
easat-8653	108	45	area	area	NOUN
easat-8653	108	46	,	,	PUNCT
easat-8653	108	47	"	"	PUNCT
easat-8653	108	48	jama	jama	NOUN
easat-8653	108	49	,	,	PUNCT
easat-8653	108	50	vol	vol	NOUN
easat-8653	108	51	.	.	PROPN
easat-8653	108	52	323	323	NUM
easat-8653	108	53	,	,	PUNCT
easat-8653	108	54	no	no	INTJ
easat-8653	108	55	.	.	NOUN
easat-8653	108	56	20	20	NUM
easat-8653	108	57	,	,	PUNCT
easat-8653	108	58	pp	pp	ADJ
easat-8653	108	59	.	.	PUNCT
easat-8653	109	1	2052	2052	NUM
easat-8653	109	2	-	-	SYM
easat-8653	109	3	2059	2059	NUM
easat-8653	109	4	,	,	PUNCT
easat-8653	109	5	2020	2020	NUM
easat-8653	109	6	.	.	PUNCT
easat-8653	110	1	https://doi.org/10.1001/jama.2020.6775	https://doi.org/10.1001/jama.2020.6775	PROPN
easat-8653	110	2	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
easat-8653	110	3	https://doi.org/10.1016/j.jinf.2020.04.021	https://doi.org/10.1016/j.jinf.2020.04.021	NOUN
easat-8653	110	4	https://doi.org/10.1016/j.hemonc.2020.07.005	https://doi.org/10.1016/j.hemonc.2020.07.005	VERB
easat-8653	110	5	https://doi.org/10.1016/s0140-6736(20)30211-7	https://doi.org/10.1016/s0140-6736(20)30211-7	CCONJ
easat-8653	110	6	https://doi.org/10.1001/jama.2020.6775	https://doi.org/10.1001/jama.2020.6775	PROPN